AB 528: Controlled substances: CURES database.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2019-10-09
|
Date
|
Status
|
|---|---|
| Oct 9, 2019 | Chaptered by Secretary of State - Chapter 677, Statutes of 2019. |
| Oct 9, 2019 | Approved by the Governor. |
| Sep 26, 2019 | Enrolled and presented to the Governor at 4 p.m. |
| Sep 13, 2019 | Senate amendments concurred in. To Engrossing and Enrolling. |
| Sep 12, 2019 | Joint Rule 62(a), file notice suspended. |
| Sep 11, 2019 | Assembly Rule 77 suspended. |
| Sep 10, 2019 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after September 12 pursuant to Assembly Rule 77. |
| Sep 10, 2019 | Read third time. Passed. Ordered to the Assembly. |
| Sep 9, 2019 | Read second time. Ordered to third reading. |
| Sep 6, 2019 | Read third time and amended. Ordered to second reading. |
| Sep 5, 2019 | Ordered to third reading. |
| Sep 4, 2019 | Ordered to special consent calendar. |
| Aug 30, 2019 | From committee: Do pass. (Ayes 7. Noes 0.) (August 30). |
| Aug 12, 2019 | In committee: Referred to APPR. suspense file. |
| Jul 5, 2019 | Withdrawn from committee. |
| Jul 3, 2019 | Read second time and amended. Re-referred to Com. on RLS. |
| Jul 2, 2019 | From committee: Amend, and do pass as amended and re-refer to Com. on RLS. (Ayes 8. Noes 0.) (July 1). |
| Jun 19, 2019 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on B., P. & E.D. |
| Jun 6, 2019 | In committee: Hearing postponed by committee. |
| May 16, 2019 | Referred to Com. on B., P. & E.D. |
| May 2, 2019 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 2, 2019 | Read third time. Urgency clause adopted. Passed. Ordered to the Senate. |
| Apr 25, 2019 | Read second time. Ordered to third reading. |
| Apr 24, 2019 | From committee: Do pass. (Ayes 18. Noes 0.) (April 24). |
| Apr 9, 2019 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 19. Noes 0.) (April 9). Re-referred to Com. on APPR. |
| Feb 21, 2019 | Referred to Com. on B. & P. |
| Feb 14, 2019 | From printer. May be heard in committee March 16. |
| Feb 13, 2019 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 13, 2019 | AB 528 Low Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Sep 13, 2019 | With recommendation: That Senate amendments be concurred in. | Assembly Standing Committee on Business and Professions |
Passed |
|
| Sep 10, 2019 | Assembly 3rd Reading AB528 Low By Pan | Senate Floor |
Passed |
|
| Aug 30, 2019 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 12, 2019 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jul 1, 2019 | Do pass as amended, but first amend, and re-refer to the Committee on [Rules] | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
|
| May 2, 2019 | AB 528 Low Third Reading Urgency | Assembly Floor |
Passed |
|
| Apr 24, 2019 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 9, 2019 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
CONCURRENCE IN SENATE AMENDMENTS
CSA2 Bill Id:AB 528
Author:(Low)
As Amended Ver:September 6, 2019
Majority vote
SUMMARY:
Changes the required timeframe in which pharmacists are required to report dispensed prescriptions to the state's prescription drug monitoring program (PDMP), Controlled Substance Utilization Review and Evaluation System (CURES), from seven days to the following working day; authorizes physicians and surgeons who are licensed by the Medical Board of California (MBC) but do not possess a federal Drug Enforcement Agency (DEA) registration to register for access to CURES; requires pharmacists to report Schedule V drugs to CURES; expands the authority for a prescriber's licensed delegate to retrieve data from CURES on behalf of that prescriber; makes other technical and clarifying changes to laws governing the state's PDMP.
The Senate Amendments:
- Delay implementation of the majority of the bill by a year, with remaining provisions delayed by a year and a half or until the Department of Justice (DOJ) promulgates effecting regulations.
- Add the requirement for pharmacists to report Schedule V drugs to CURES.
- Expand access to CURES for delegates acting on behalf of licensed prescribers.
- Change the reporting timeline from one working day following the date a prescription is dispensed to one working day following the date a prescription is released to the patient.
- Adjust the timeline on which a prescriber must re-query the CURES database prior to renewing a prescription for Schedule II-IV drugs from once every four months to once every six months as long as opioids remain part of the treatment and are being renewed.
- Make other clarifying and technical changes to a prescriber's duty to consult CURES.
- Authorize physicians and surgeons who are licensed by the Medical Board of California MBC but do not possess a federal DEA registration to register for access to CURES.
COMMENTS:
CURES database. CURES is the state's PDMP, allowing health professionals, regulators, and law enforcement to conduct web-based searches of the system to inform prescribing practices and support investigations. Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists are required to report basic information about the patient and their prescription within 7 days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient's prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee's prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Reporting Timelines. Currently, statute requires dispensers to report new prescriptions to CURES "as soon as reasonably possible, but not more than seven days." This means while data in the CURES 2.0 system is "real-time" in that reported prescriptions immediately appear in the database, for up to one week a dispensed prescription may not be appear in users' queries. Meanwhile, "doctor shoppers" are able to visit multiple prescribers to obtain prescriptions.
Reducing the amount of time provided to dispensers to report prescriptions to CURES from up to 7 days down to within the next business day will significantly improve the database's reliability for practitioners seeking to identify multi-prescriber seeking behavior among their patients. The change would not substantially change current practice for the vast majority of pharmacies. It will, however, ensure that doctor shoppers are not able to take advantage of a time delay when seeking to obtain multiple prescriptions.
Schedule V Drugs. Because prescriptions for Schedule V drugs have been deemed by the DEA to represent those regulated by the Controlled Substances Act with the lowest potential for abuse, an argument has been made that the state's PDMP has no need to track them. However, assertions that Schedule V drugs like cough syrup with codeine were ultimately proven to be drastically misguided. Abuse of prescription-strength cough syrup containing codeine exploded as recreational use of the drug became popularized by hip-hop culture. Referred to through common slang terms like "purple drank," "sizzurp," "lean," and "dirty sprite," it has been widely reported that the theft of cough syrup containing codeine is one of the most prevalent causes for pharmacy break-ins.
Not all Schedule V drugs represent the same propensity for abuse and diversion as opioid-containing cough syrups. However, consistently requiring dispensers to report all Schedule V drugs is the most straightforwardly implementable way of expanding existing reporting requirements for pharmacies. AB 1752 (Low) of 2018 does not add Schedule V drugs to other mandates under California law relating to Schedule II-IV drugs; it does not, for example, add a requirement that health practitioners consult CURES prior to writing prescriptions for these substances. Tracking the drugs in the database will, however, significantly assist health professionals, regulators, and law enforcement in investigating cases of theft and abuse among these controlled substances.
Delegate Access to CURES. Currently, licensed delegates may apply for access to CURES through the DOJ and are authorized to make patient activity report (PAR) requests on behalf of prescribers. However, those delegates are not authorized to view the information on the report, and are therefore not allowed to actually retrieve, open, and print the report for inclusion in a patient's chart, requiring each prescriber to log into CURES and retrieve the report themselves. This bill would provide delegates with fuller access to PARs, within existing medical privacy requirements, for purposes of assisting prescribers who are required to consult those reports.
According to the Author:
"PDMPs are recognized by experts as a powerful tool to combat the abuse and diversion of prescription drugs like opioids. Data reported to CURES provides health professionals, regulators, and law enforcement with critical information to promote safe prescribing and identify abuse. AB 1752 improves these reports. Adding Schedule V drugs to CURES allows CURES to track frequently stolen or abused drugs like cough syrups containing opioids, addressing a serious deficiency in the database. Reducing the time a pharmacist has to report to CURES from 7 days to one working day prevents 'doctor shoppers' from visiting multiple prescribers over the course of a whole week to obtain multiple prescriptions. With this bill, CURES will function even better to help combat the opioid crisis."
Arguments in Support:
The California Medical Association (CMA) supports the bill. The CMA states that "In order for a physician to make the most informed decision when prescribing a controlled substance to a patient, they must know what medication the patient is currently taking. This bill would ensure that the physician has up-to-date information on any controlled substances a patient is taking to within one day of dispensing. This information is critically important to both the physician and the safety of the patient."
Arguments in Opposition:
The American Civil Liberties Union (ACLU) writes that "while we appreciate your interest in addressing opioid abuse, it has become very clear that one of the biggest reasons for the opioid epidemic is reprehensible behavior by Purdue Pharma, which was well aware of OxyContin abuse." The ACLU states that it opposes the bill "unless it is amended to either delete the addition of Schedule V Drugs to the CURES database or to prevent unnecessary disclosure of private patient information."
FISCAL COMMENTS:
According to the Senate Committee on Appropriations, approximately $874,000 to the DOJ in fiscal year (FY) 2019/20, $1.5 million in FY 2020/21, and $496,000 in FY 2022/23 to implement the bill's technological upgrades, which would be subject to reimbursement from the CURES Fund as administered by the Department of Consumer Affairs.
VOTES:
ASM BUSINESS AND PROFESSIONS: 19-0-1
YES: Low, Brough, Bloom, Chen, Chiu, Cunningham, Dahle, Eggman, Fong, Gipson, Gloria, Grayson, Holden, Irwin, McCarty, Medina, Mullin, Ting, Wood
ABS, ABST OR NV: Obernolte
ASM APPROPRIATIONS: 18-0-0
YES: Gonzalez, Bigelow, Bloom, Bonta, Brough, Calderon, Carrillo, Chau, Diep, Eggman, Fong, Gabriel, Jones-Sawyer, Maienschein, Obernolte, Petrie-Norris, Quirk, Robert Rivas
ASSEMBLY FLOOR: 77-0-3
YES: Aguiar-Curry, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Muratsuchi, Nazarian, O'Donnell, Obernolte, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
ABS, ABST OR NV: Arambula, Mullin, Quirk
SENATE FLOOR: 38-1-1
YES: Allen, Archuleta, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dahle, Dodd, Durazo, Galgiani, Glazer, Lena Gonzalez, Grove, Hertzberg, Hill, Hueso, Hurtado, Jones, Leyva, McGuire, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Stone, Umberg, Wieckowski, Wiener, Wilk
NO: Jackson
ABS, ABST OR NV: Atkins
ASM BUSINESS AND PROFESSIONS: 19-0-0
YES: Low, Brough, Arambula, Bloom, Chen, Chiu, Cunningham, Eggman, Fong, Gipson, Gloria, Grayson, Holden, Irwin, McCarty, Medina, Mullin, Obernolte, Ting
UPDATED:
VERSION: September 6, 2019
CONSULTANT: Robert Sumner / B. & P. / (916) 319-3301 FN: 0002467
Date of Hearing: September 12, 2019
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 528
Author:(Low) – As Amended Ver:September 6, 2019
NOTE: This bill has been re-referred to the Committee pursuant to Rule 77.2.
SUBJECT: Controlled substances: CURES database.
SUMMARY: Changes the required timeframe in which pharmacists are required to report dispensed prescriptions to the state’s prescription drug monitoring program (PDMP) from seven days to the following working day; authorizes physicians and surgeons who are licensed by the Medical Board of California (MBC) but do not possess a federal DEA registration to register for access to CURES; requires pharmacists to report Schedule V drugs to CURES; expands the authority for a prescriber’s licensed delegate to retrieve data from CURES on behalf of that prescriber; makes other technical and clarifying changes to laws governing the state’s PDMP.
EXISTING LAW:
- Allows only a physician, dentist, podiatrist, veterinarian, naturopathic doctor, registered nurse, certified nurse-midwife, optometrist, or out-of-state prescriber to write or issue a prescription. (Health and Safety Code (HSC) § 11150)
- States that a prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice, and that the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. (HSC § 11153)
- Prohibits medical professionals from prescribing, administering, or dispensing a controlled substance to an addict, as defined. (HSC § 11156)
- Establishes the Controlled Substance Utilization Review and Evaluation System (CURES), a PDMP maintained by the California Department of Justice (DOJ) for the purposes of collecting records of dispensed controlled substances for review by licensed prescribers and dispensers, regulatory investigators, law enforcement, and statistical researchers. (HSC § 11165(a))
- Requires pharmacists and other dispensers to report information to CURES within 7 days relating to prescriptions of Schedule II, III, and IV controlled substances. (HSC § 11165(d))
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) registration providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Requires certain health care practitioners to consult the CURES database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC § 11165.4)
- Requires the DOJ to upgrade CURES to allow health information technology systems that meet certain patient privacy and data security requirements to interoperate with the database, allowing prescribers and dispensers to make queries through their electronic health record applications. (HSC § 11165.1)
- Prohibits any person from obtaining or attempting to obtain a prescription for controlled substances, by fraud, deceit, misrepresentation, subterfuge, or the concealment of a material fact. (HSC § 11173)
- Enables security printers and prescribers to report stolen or lost prescription pads to the DOJ through CURES. (HSC § 11165.3)
- Provides dedicated funding for the CURES program through an annual license fee of $6 assessed for licensees authorized to prescribe or dispense controlled substances in California. (Business and Professions Code (BPC) § 208)
- Authorizes the DOJ to seek voluntarily contributed private funds from insurers, health care service plans, qualified manufacturers, and other donors for the purpose of supporting CURES. (HSC § 11165.5)
- Allows the DOJ to conduct audits of CURES and its users and issue citations and fines for system misuse. (HSC § 11165.2)
- Requires the CURES database to comply with all applicable federal and state privacy and security laws and regulations and requires the DOJ to establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES. (HSC § 11165(c))
THIS BILL:
- Changes the required timeline for dispensers to report prescription information to CURES from no later than seven days to within the following working day.
- Requires reports to CURES to be made within the necessary time frame following the date a prescription is released to the patient or patient’s representative, rather than the date a prescription is dispensed.
- Authorizes physicians and surgeons who are licensed by the MBC but do not possess a federal DEA registration to register for access to CURES.
- Requires pharmacists to report Schedule V drugs to CURES.
- Expands the authority for a prescriber’s licensed delegate to retrieve data from CURES on behalf of that prescriber.
- Makes other technical and clarifying changes to laws governing the state’s PDMP.
FISCAL EFFECT: According to the Senate Committee on Appropriations, approximately $874,000 to the DOJ in FY 2019/20, $1.5 million in FY 2020/21, and $496,000 in FY 2022/23 to implement the bill’s technological upgrades, which would be subject to reimbursement from the CURES Fund as administered by the Department of Consumer Affairs.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author:
“PDMPs are recognized by experts as a powerful tool to combat the abuse and diversion of prescription drugs like opioids. Data reported to CURES provides health professionals, regulators, and law enforcement with critical information to promote safe prescribing and identify abuse. AB 528 improves these reports. Reducing the time a pharmacist has to report to CURES from 7 days to one working day prevents ‘doctor shoppers’ from visiting multiple prescribers over the course of a whole week to obtain multiple prescriptions. With this bill, CURES will function even better to help combat the opioid crisis.”
Background.
Overview of the Opioid Crisis. In October of 2017, the White House declared the opioid crisis a public health emergency, formally recognizing what had long been understood to be a growing epidemic responsible for devastation in communities across the country. According to the Centers for Disease Control and Prevention, as many as 50,000 Americans died of an opioid overdose in 2016, representing a 28 percent increase over the previous year. Additionally, the number of Americans who died of an overdose of fentanyl and other opioids more than doubled during that time with nearly 20,000 deaths. These death rates compare to, and potentially exceed, those at the height of the AIDS epidemic.
Opioids are a class of drugs prescribed and administered by health professionals to manage pain. Modern use of the term “opioid” typically describes both naturally occurring opiates derived from the opium poppy as well as their manufactured synthetics. Common examples of prescription opioids include oxycodone (OxyContin, Percocet); hydrocodone (Vicodin, Norco, Lorcet); codeine; morphine; and fentanyl. Heroin is also an opioid.
In addition to providing pain relief, opioids can be used as a cough suppressant, an antidiarrheal, a method of sedation, and a treatment for shortness of breath. The majority of pharmaceutical opioids are Schedule II drugs under the federal Controlled Substances Act, considered by the federal Drug Enforcement Agency (DEA) to have a high potential for abuse that may lead to severe psychological or physical dependence. However, combination drugs containing lower doses of opioids combined with other active ingredients are typically less restricted; for example, cough syrups containing low doses of codeine are frequently classified Schedule V medications.
The abuse of prescription drugs was historically viewed as a criminal concern analogous to street narcotics cases regularly investigated by law enforcement. In recent years, however, an expert consensus has evolved around the opinion that the opioid crisis must be addressed through the lens of public health policy. This belief is supported by research demonstrating how health professionals may have inadvertently contributed to the origins of the crisis. It is widely accepted that health professionals will play a necessarily critical role in any meaningful solutions.
In the opioid crisis’s broader national context, there has been a persistent perception that California represents a relatively minor segment of an epidemic more typically identified with states like New Hampshire and West Virginia. However, there is substantial evidence that communities in California have been much harder hit than may be generally believed. For example, in 2015, several rural counties in California saw as many or more drug overdose deaths per 100,000 residents than some Midwestern states. It has been reported than some small counties had more opioid prescriptions than residents. In total, the California Department of Public Health estimates that nearly 2,000 Californians died of an opioid overdose in 2016.
In February of 2018, a bipartisan coalition of California State Assemblymembers announced a package of legislation aimed at combating the opioid crisis. The bills have been presented as representing a diversity of approaches to curbing overprescription, encouraging treatment, and preventing diversion. The potential of each proposed measure to effectively address the epidemic of prescription drug abuse must be evaluated in proportion to any added burden to those health professionals who remain tasked with ensuring that legitimate treatment continues to be provided to patients with pain management needs.
CURES Database. CURES was first established in 1996 as a “technologically sophisticated” database containing prescription records collected through California’s Triplicate Prescription Program, which provided the DOJ with copies of all Schedule II drug prescriptions. Subsequent legislation made CURES the state’s sole prescription record repository and added Schedule III and IV drugs to the database. In 2008, CURES was upgraded to function as a PDMP, allowing health professionals, regulators, and law enforcement to conduct web-based searches of the system to inform prescribing practices and support investigations.
Budget problems later plagued the database as the elimination of the DOJ’s Bureau of Narcotics Enforcement effectively defunded the CURES program. Users of the system complained that the PDMP offered insufficient client support and was plagued with technical issues. In response, Attorney General Kamala D. Harris sponsored legislation to overhaul the database with revenue newly derived from a $6 license fee for healing arts professionals. The resulting system, commonly referred to as “CURES 2.0,” is considered to be a significantly improved, state-of-the-art tool for addressing the abuse and diversion of opioids and other prescription drugs.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists are required to report basic information about the patient and their prescription within 7 days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Over 50 million prescription records have been uploaded into the system by dispensing pharmacists since the beginning of the CURES program. As of January 1, 2018, 170,422 users had been approved for access to the system. Last year, close to 10 million activity reports had been processed by practitioners, pharmacists, law enforcement, and regulatory users. The vast majority of these searches (over 99%) were queries made by prescribers and dispensers seeking to review a patient’s prescription history as a component of exercising informed clinical judgment before providing access to opioids or other controlled substances.
Access to CURES is limited by a number of state and federal privacy laws. This includes the Health Insurance Portability and Accountability Act (HIPAA), the California Medical Information Act, and the Information Practices Act. Whether law enforcement use of the system implicates the Fourth Amendment’s protections against unreasonable searches remains a topic of debate. In 2017, the Supreme Court of California ruled in Lewis v. Superior Court that privacy interests are justified by the state’s interest in preventing drug diversion and protecting patients.
As of October 2018, health practitioners are required to consult the CURES database prior to writing a prescription for a Schedule II, III, or IV drug for the first time, and then at least once every four months as long as the prescription continues to be renewed. Other recently enacted statutes require the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements. As attention to the opioid crisis continues to grow, CURES and other PDMPs are regularly mentioned as powerful tools for curbing the abuse of prescription drugs.
Schedule V Drugs. The federal Controlled Substances Act classifies a number of drugs and chemicals into one of five schedules. Schedule I drugs (such as cannabis, heroin, and ecstasy) have been determined to have no currently accepted medical use and a high potential for abuse. Schedule I drugs may not be prescribed by any health practitioner in the United States. Drugs falling within Schedules II through V may be prescribed only by health practitioners in possession of a DEA registration and are ranked according to the drug’s potential for abuse, with lower numbered schedules representing drugs with a higher risk of abuse or dependence.
Schedule V drugs are considered by the DEA to have “lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics.” DEA specifies examples of Schedule V drugs as including cough preparations with less than 200 milligrams of codein, an opioid. These cough syrups, such as Robitussin AC, are not available on shelves or over the counter and a prescription by a DEA registered practitioner is always required for any pharmacy to dispense the drug. Other non-opioid examples of Schedule V drugs include pregabalin (Lyrica) and diphenoxylate (Lomotil).
When CURES was first created in 1996, it contained only records of Schedule II drugs because these were the prescriptions that had already been tracked by the Triplicate Prescription Program since 1939. Additional controlled substances were added incrementally through legislation, with Schedule III drugs added in 2003 and Schedule IV drugs added in 2006. Funding for CURES was effectively eliminated through $71 million in budget cuts to the DOJ in 2011, and the system wouldn’t receive a sustained funding source and an upgraded technology architecture until 2013. Once the CURES program was refunded and revamped, discussion resumed as to whether reporting requirements should be expanded to include Schedule V drugs (the last uncollected class of federally controlled substances).
Because prescriptions for Schedule V drugs have been deemed by the DEA to represent those regulated by the Controlled Substances Act with the lowest potential for abuse, an argument has been made that the state’s PDMP has no need to track them. However, assertions that Schedule V drugs like cough syrup with codeine were ultimately proven to be drastically misguided. Abuse of prescription-strength cough syrup containing codeine exploded as recreational use of the drug became popularized by hip-hop culture. Referred to through common slang terms like “purple drank,” “sizzurp,” “lean,” and “dirty sprite,” it has been widely reported that the theft of cough syrup containing codeine is one of the most prevalent causes for pharmacy break-ins.
Not all Schedule V drugs represent the same propensity for abuse and diversion as opioid-containing cough syrups. However, consistently requiring dispensers to report all Schedule V drugs is the most straightforwardly implementable way of expanding existing reporting requirements for pharmacies. AB 1752 does not add Schedule V drugs to other mandates under California law relating to Schedule II-IV drugs; it does not, for example, add a requirement that health practitioners consult CURES prior to writing prescriptions for these substances. Tracking the drugs in the database will, however, significantly assist health professionals, regulators, and law enforcement in investigating cases of theft and abuse among these controlled substances.
CURES Reporting Timelines. Currently, statute requires dispensers to report new prescriptions to CURES “as soon as reasonably possible, but not more than seven days.” This means while data in the CURES 2.0 system is “real-time” in that reported prescriptions immediately appear in the database, for up to one week a dispensed prescription may not be appear in users’ queries. Meanwhile, “doctor shoppers” are able to visit multiple prescribers to obtain prescriptions.
The majority of pharmacies in California do not report prescriptions directly into CURES. Atlantic Associates, a technology vendor, operates a Direct Dispense Application that facilitates reports between pharmacists and CURES. This application typically collects all Schedule II-IV prescriptions dispensed by the pharmacy each day and uploads them all into CURES overnight in a single batch process. The standard turnaround time for these uploads is within one day. While some pharmacies with smaller numbers of daily prescriptions manually upload files to CURES, this process is nearly universal for most prescriptions dispensed within the state.
Reducing the amount of time provided to dispensers to report prescriptions to CURES from up to 7 days down to within the next business day will significantly improve the database’s reliability for practitioners seeking to identify multi-prescriber seeking behavior among their patients. The change would not substantially change current practice for the vast majority of pharmacies. It will, however, ensure that doctor shoppers are not able to take advantage of a time delay when seeking to obtain multiple prescriptions.
Delegate Access to CURES. Currently, licensed delegates may apply for access to CURES through the DOJ and are authorized to make patient activity report (PAR) requests on behalf of prescribers. However, those delegates are not authorized to view the information on the report, and are therefore not allowed to actually retrieve, open, and print the report for inclusion in a patient’s chart, requiring each prescriber to log into CURES and retrieve the report themselves. This bill would provide delegates with fuller access to PARs, within existing medical privacy requirements, for purposes of assisting prescribers who are required to consult those reports.
Prior Related Legislation. AB 1751 (Low, Chapter 478, Statutes of 2018) provides a framework for the CURES PDMP to connect with other states that comply with California’s patient privacy and data security standards.
AB 1752 (Low) would have reduced the required timeframe in which pharmacists are required to report dispensed prescriptions to CURES from seven days to the following business day and would have added Schedule V drugs to CURES. This bill was held under submission on the Senate Appropriations suspense file.
AB 1753 (Low, Chapter 479, Statutes of 2018) allows the DOJ links uniquely serialized prescription pads with CURES.
AB 2086 (Gallagher, Chapter 274, Statutes of 2018) allows prescribers of controlled substances to review a list of patients for whom they are listed as being the prescriber in CURES.AB 3042 (Takasugi, Chapter 345, Statutes of 2002) first established CURES as a pilot project operating concurrently with the state’s Triplicate Prescription Program.
SB 151 (Burton, Chapter 406, Statutes of 2003) made CURES the state’s permanent prescription tracking program and added Schedule III drugs to the database.
SB 734 (Torlakson, Chapter 487, Statutes of 2005) created the framework to upgrade the CURES prescription database into a searchable, client-facing PDMP.
AB 2986 (Mullin, Chapter 286, Statutes of 2006) added Schedule IV drugs to the CURES database.
SB 809 (DeSaulnier, Chapter 400, Statutes of 2013) established new healing arts license fees to fund the development and maintenance a new and improved “CURES 2.0” database.
SB 482 (Lara, Chapter 708, Statutes of 2016) mandated that health practitioners consult a patient’s history in CURES prior to prescribing them a Schedule II, III, or IV controlled substance for the first time and then at least once every four months as long as the prescription continued to be renewed.
AB 40 (Santiago, Chapter 607, Statutes of 2017) required the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements.
ARGUMENTS IN SUPPORT:
The California Medical Association (CMA) supports the bill. The CMA states that “In order for a physician to make the most informed decision when prescribing a controlled substance to a patient, they must know what medication the patient is currently taking. This bill would ensure that the physician has up-to-date information on any controlled substances a patient is taking to within one day of dispensing. This information is critically important to both the physician and the safety of the patient.”
ARGUMENTS IN OPPOSITION:
The American Civil Liberties Union (ACLU) writes that “while we appreciate your interest in addressing opioid abuse, it has become very clear that one of the biggest reasons for the opioid epidemic is reprehensible behavior by Purdue Pharma, which was well aware of OxyContin abuse.” The ACLU states that it opposes the bill “unless it is amended to either delete the addition of Schedule V Drugs to the CURES database or to prevent unnecessary disclosure of private patient information.”
REGISTERED SUPPORT:
California Academy of Child and Adolescent Psychiatry
California Academy of Family Physicians
California Chapter of the American College of Emergency Physicians
California Chiropractic Association
California Dental Association
California Medical Association
California Narcotics Officers’ Association
California Pharmacists Association
California Radiological Society
California Veterinary Medical Association
CaliforniaHealth+ Advocates
County Behavioral Health Directors Association
County of San Diego
Medical Board of California
Ochin, Inc.
REGISTERED OPPOSITION:
American Civil Liberties Union
Electronic Frontier Foundation
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 528
Author:(Low)
As Amended Ver:September 6, 2019
Majority vote
SUMMARY:
Changes the required timeframe in which pharmacists are required to report dispensed prescriptions to the state's prescription drug monitoring program (PDMP), CURES, from seven days to the following working day; authorizes physicians and surgeons who are licensed by the Medical Board of California (MBC) but do not possess a federal Drug Enforcement and Administration (DEA) registration to register for access to CURES; requires pharmacists to report Schedule V drugs to CURES; expands the authority for a prescriber's licensed delegate to retrieve data from CURES on behalf of that prescriber; makes other technical and clarifying changes to laws governing the state's PDMP.
The Senate Amendments:
- Delay implementation of the majority of the this by a year, with remaining provisions delayed by a year and a half or until the Department of Justice (DOJ) promulgates effecting regulations.
- Add the requirement for pharmacists to report Schedule V drugs to CURES.
- Expand access to CURES for delegates acting on behalf of licensed prescribers.
- Change the reporting timeline from one working day following the date a prescription is dispensed to one working day following the date a prescription is released to the patient.
- Adjust the timeline on which a prescriber must re-query the CURES database prior to renewing a prescription for Schedule II-IV drugs from once every four months to once every six months as long as opioids remain part of the treatment and are being renewed.
- Make other clarifying and technical changes to a prescriber's duty to consult CURES.
- Authorize physicians and surgeons who are licensed by the Medical Board of California MBC but do not possess a federal DEA registration to register for access to CURES.
COMMENTS:
CURES database. CURES is the state's PDMP, allowing health professionals, regulators, and law enforcement to conduct web-based searches of the system to inform prescribing practices and support investigations. Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists are required to report basic information about the patient and their prescription within seven days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient's prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee's prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Reporting Timelines. Currently, statute requires dispensers to report new prescriptions to CURES "as soon as reasonably possible, but not more than seven days." This means while data in the CURES 2.0 system is "real-time" in that reported prescriptions immediately appear in the database, for up to one week a dispensed prescription may not be appear in users' queries. Meanwhile, "doctor shoppers" are able to visit multiple prescribers to obtain prescriptions.
Reducing the amount of time provided to dispensers to report prescriptions to CURES from up to 7 days down to within the next business day will significantly improve the database's reliability for practitioners seeking to identify multi-prescriber seeking behavior among their patients. The change would not substantially change current practice for the vast majority of pharmacies. It will, however, ensure that doctor shoppers are not able to take advantage of a time delay when seeking to obtain multiple prescriptions.
Schedule V Drugs. Because prescriptions for Schedule V drugs have been deemed by the DEA to represent those regulated by the Controlled Substances Act with the lowest potential for abuse, an argument has been made that the state's PDMP has no need to track them. However, assertions that Schedule V drugs like cough syrup with codeine were ultimately proven to be drastically misguided. Abuse of prescription-strength cough syrup containing codeine exploded as recreational use of the drug became popularized by hip-hop culture. Referred to through common slang terms like "purple drank," "sizzurp," "lean," and "dirty sprite," it has been widely reported that the theft of cough syrup containing codeine is one of the most prevalent causes for pharmacy break-ins.
Not all Schedule V drugs represent the same propensity for abuse and diversion as opioid-containing cough syrups. However, consistently requiring dispensers to report all Schedule V drugs is the most straightforwardly implementable way of expanding existing reporting requirements for pharmacies. AB 1752 (Low) of 2018 does not add Schedule V drugs to other mandates under California law relating to Schedule II-IV drugs; it does not, for example, add a requirement that health practitioners consult CURES prior to writing prescriptions for these substances. Tracking the drugs in the database will, however, significantly assist health professionals, regulators, and law enforcement in investigating cases of theft and abuse among these controlled substances.
Delegate Access to CURES. Currently, licensed delegates may apply for access to CURES through the DOJ and are authorized to make patient activity report (PAR) requests on behalf of prescribers. However, those delegates are not authorized to view the information on the report, and are therefore not allowed to actually retrieve, open, and print the report for inclusion in a patient's chart, requiring each prescriber to log into CURES and retrieve the report themselves. This bill would provide delegates with fuller access to PARs, within existing medical privacy requirements, for purposes of assisting prescribers who are required to consult those reports.
According to the Author:
"PDMPs are recognized by experts as a powerful tool to combat the abuse and diversion of prescription drugs like opioids. Data reported to CURES provides health professionals, regulators, and law enforcement with critical information to promote safe prescribing and identify abuse. AB 1752 improves these reports. Adding Schedule V drugs to CURES allows CURES to track frequently stolen or abused drugs like cough syrups containing opioids, addressing a serious deficiency in the database. Reducing the time a pharmacist has to report to CURES from 7 days to one working day prevents 'doctor shoppers' from visiting multiple prescribers over the course of a whole week to obtain multiple prescriptions. With this bill, CURES will function even better to help combat the opioid crisis."
Arguments in Support:
The California Medical Association (CMA) supports the bill. The CMA states that "In order for a physician to make the most informed decision when prescribing a controlled substance to a patient, they must know what medication the patient is currently taking. This bill would ensure that the physician has up-to-date information on any controlled substances a patient is taking to within one day of dispensing. This information is critically important to both the physician and the safety of the patient."
Arguments in Opposition:
The American Civil Liberties Union (ACLU) writes that "while we appreciate your interest in addressing opioid abuse, it has become very clear that one of the biggest reasons for the opioid epidemic is reprehensible behavior by Purdue Pharma, which was well aware of OxyContin abuse." The ACLU states that it opposes the bill "unless it is amended to either delete the addition of Schedule V Drugs to the CURES database or to prevent unnecessary disclosure of private patient information."
FISCAL COMMENTS:
According to the Senate Committee on Appropriations, approximately $874,000 to the DOJ in FY 2019/20, $1.5 million in FY 2020/21, and $496,000 in FY 2022/23 to implement the bill's technological upgrades, which would be subject to reimbursement from the CURES Fund as administered by the Department of Consumer Affairs.
VOTES:
ASM BUSINESS AND PROFESSIONS: 19-0-1
YES: Low, Brough, Bloom, Chen, Chiu, Cunningham, Dahle, Eggman, Fong, Gipson, Gloria, Grayson, Holden, Irwin, McCarty, Medina, Mullin, Ting, Wood
ABS, ABST OR NV: Obernolte
ASM APPROPRIATIONS: 18-0-0
YES: Gonzalez, Bigelow, Bloom, Bonta, Brough, Calderon, Carrillo, Chau, Diep, Eggman, Fong, Gabriel, Jones-Sawyer, Maienschein, Obernolte, Petrie-Norris, Quirk, Robert Rivas
ASSEMBLY FLOOR: 77-0-3
YES: Aguiar-Curry, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Muratsuchi, Nazarian, O'Donnell, Obernolte, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
ABS, ABST OR NV: Arambula, Mullin, Quirk
SENATE FLOOR: 38-1-1
YES: Allen, Archuleta, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dahle, Dodd, Durazo, Galgiani, Glazer, Lena Gonzalez, Grove, Hertzberg, Hill, Hueso, Hurtado, Jones, Leyva, McGuire, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Stone, Umberg, Wieckowski, Wiener, Wilk
NO: Jackson
ABS, ABST OR NV: Atkins
UPDATED:
VERSION: September 6, 2019
CONSULTANT: Robert Sumner / B. & P. / (916) 319-3301 FN: 0002404
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 528 |
THIRD READING
Bill No: AB 528
Amended: 9/6/19 in Senate
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 8-0, 7/1/19
AYES: Glazer, Archuleta, Dodd, Galgiani, Hill, Leyva, Pan, Wilk
NO VOTE RECORDED: Chang
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/30/19
AYES: Portantino, Bates, Bradford, Durazo, Hill, Jones, Wieckowski
ASSEMBLY FLOOR: 77-0, 5/2/19 - See last page for vote
SUBJECT: Controlled substances: CURES database
DIGEST:
This bill adds Schedule V drugs to the Controlled Substances Utilization Review and Evaluation System (CURES); changes the required timeframe in which pharmacists are required to report dispensed prescriptions from seven days to the following business day; and makes other technical changes.
Senate Floor Amendments of 9/6/19 delay most provisions of this bill until January 1, 2021; change the trigger for the next-day reporting deadline from the date a prescription is dispensed to the date it is actually released to the patient or the patient’s representative; provide for a safe harbor from the reporting requirement in the event of a natural disaster or power outage; and delete language authorizing a physician who is temporarily filling in for another physician to write a prescription without consulting CURES.
Existing law:
- Establishes CURES for the electronic monitoring of Schedule II, III and IV controlled substance prescriptions. CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the Department of Justice (DOJ) no more than seven days from the time prescriptions are dispensed. (HSC § 11165)
- States that the purpose of CURES is to assist law enforcement and regulatory agencies in controlling diversion and abuse of Schedule II, III and IV controlled substances and for statistical analysis, education and research. (HSC § 11165 (a))
- Establishes privacy protections for patient data and specifies that the operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations. (HSC §§ 11165 (c) (1), (c) (2) (A), and (c) (3))
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) registration providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Requires certain health care practitioners to consult the CURES database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC § 11165.4)
This bill:
- Expands the drugs required to be reported and monitored in CURES to include Schedule V controlled substances.
- Changes the required timeframe in which dispensers are required to report dispensed prescriptions from seven days to one working day.
- Authorizes a licensed physician and surgeon who does not hold a DEA registration to submit an application to obtain approval to access CURES information.
- Clarifies patient activity report authority for individuals delegated by prescribers or dispensers to access information.
Background
Through the Controlled Substances Act of 1970, the federal government regulates the manufacture, distribution and dispensing of controlled substances. The act ranks into five schedules those drugs known to have potential for physical or psychological harm, based on three considerations: (1) their potential for abuse; (2) their accepted medical use; and, (3) their accepted safety under medical supervision. Schedule I controlled substances have a high potential for abuse and no generally accepted medical use such as heroin, ecstasy, and LSD; Schedule II controlled substances have a currently accepted medical use in treatment, or a currently accepted medical use with severe restrictions, and have a high potential for abuse and psychological or physical dependence. Schedule II drugs can be narcotics or non-narcotic. Examples of Schedule II controlled substances include combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), morphine, methadone, Ritalin, Demerol, Percocet, Percodan, fentanyl and Oxycontin; Schedule III and IV controlled substances have a currently accepted medical use in treatment, less potential for abuse but are known to be mixed in specific ways to achieve a narcotic-like end product. Examples include Tylenol with codeine, testosterone, Xanax, Ambien and other anti-anxiety drugs and; Schedule V drugs have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes.
With rising levels of prescription drug abuse, prescription drug monitoring programs (PDMPs) assist law enforcement and regulatory bodies with their efforts to reduce drug abuse and diversion. In California, CURES is an electronic tracking program that reports all pharmacy (and specified types of prescriber) dispensing of certain schedules of controlled drugs by drug name, quantity, prescriber, patient, and pharmacy. Data from CURES is managed by DOJ. Information tracked in CURES contains the patient name, prescriber name, pharmacy name, drug name, amount and dosage, and is available to law enforcement agencies, regulatory bodies, prescribers, dispensers, and qualified researchers. CURES provides information to identify if a person is “doctor shopping” (when a patient, often a prescription-drug addict, visits multiple doctors to obtain multiple prescriptions for drugs, or uses multiple pharmacies to obtain prescription drugs). The system can also report on the top drugs prescribed for a specific time period, drugs prescribed in a particular county, doctor prescribing data, pharmacy dispensing data, and is a critical tool for assessing whether multiple prescriptions for the same patient may exist.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists and other dispensers are required to report basic information about the patient and their prescription within seven days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Information in CURES is not available to just anyone. Data can only be accessed by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense Schedule II, Schedule III, and Schedule IV controlled substances; appropriate state, local and federal persons or public agencies for disciplinary, civil or criminal actions; other agencies or entities, as determined by DOJ, for educating practitioners and others, in lieu of disciplinary, civil or criminal actions and; non-identifying CURES data may be provided to public and private entities for education, research, peer review and statistical analysis
The question of whether a warrant should be required for searches of CURES has extended into investigations by regulatory boards for purposes of disciplinary actions against licensees. This practice has existed since the early iterations of the database, though SB 482 (Lara, Chapter 708, Statutes of 2016) expressly limited Department of Consumer Affairs investigator searches to regulatory boards whose licensees prescribe, order, administer, furnish, or dispense controlled substances.
In 2008, the Medical Board of California (MBC) began an investigation into Dr. Alwin Carl Lewis, a licensed physician who recommended a controversial diet in which patients were encouraged to eat two meals consisting of only five bites of food each day. As part of this inquiry, MBC investigators ran a search for Dr. Lewis in CURES to determine if he had misused his prescribing privileges in addition to offering questionable nutritional advice. The search resulted in MBC filing additional charges for overprescribing. Dr. Lewis immediately sought to have the overprescribing charges dismissed on the basis that because the allegations against him relating to his diet recommendations were irrelevant to his drug prescribing history, the MBC did not have good cause to conduct the CURES search without a warrant.
Years of litigation resulted from this dispute. Dr. Lewis’s objections to the CURES search were rejected by an administrative law judge, the Los Angeles County Superior Court, and the Court of Appeal, respectively. Eventually, the case was granted review by the Supreme Court of California in Lewis v. Superior Court. In its opinion issued in July of 2017, the Court ruled in favor of the MBC. The Court found that patients did indeed have a privacy interest in their prescription records, and that the MBC’s search encroached upon this interest. However, the Court held that “even assuming the Board's actions constituted a serious intrusion on a legally protected privacy interest, its review of these records was justified by the state’s dual interest in protecting the public from the unlawful use and diversion of a particularly dangerous class of prescription drugs and protecting patients from negligent or incompetent physicians.” The balancing test employed by the Court in Lewis reflects generally the priorities that must be weighed for any CURES policies invoking patient privacy rights.
The use of CURES data remains a sensitive issue. A Los Angeles Times series, “Dying For Relief,” highlighted the role of prescription drugs in overdose deaths as determined through the examination of coroners’ reports. Reporters conducted an analysis of coroners’ reports for over 3,000 deaths occurring in four counties (Los Angeles, Orange, Ventura and San Diego) where toxicology tests found a prescription drug in the deceased’s system, usually a painkiller, anti-anxiety drug or other narcotic; coroners’ investigators reported finding a container of the same medication bearing the doctor's name, or records of a prescription; the coroner determined that the drug caused or contributed to the death. The analysis found that in nearly half of the cases where prescription drug toxicity was listed as the cause of death, there was a direct connection to a prescribing physician. The Times created a database linking overdose deaths to the doctors who prescribed drugs, and found that more than 80 of the doctors whose names were listed on prescription bottles found at the home of or on the body of a decedent had been the prescribing physician for three or more dead patients. Their analysis found that one doctor was linked to as many as 16 dead patients.
Following the veto of 2013 legislation (SB 62, Lieu), which was introduced in response to the series, and that would have required coroners in California to report to the MBC when they receive information, based on findings that were reached by, or documented and approved by, a pathologist, indicating that the cause of death was due to a Schedule II, III, or IV drug, MBC entered into a data use agreement with the California Department of Public Health (CDPH) to receive death certificate data when the death was related to opioids. According to MBC’s 2017-2018 annual report, the “death certificate project” uses information from death records to identify physicians that may be inappropriately prescribing opioids to their patients. MBC has used information from CDPH to investigate licensees who may have violated the law and has reviewed CURES prescription information, leading to matches of patients and prescribers. According to MBC, “the Board understands that just because a patient death occurred, it does not automatically mean the physician deviated from the standard of care or violated the Medical Practice Act. However, in cases where the Board determines a violation occurred, the Board takes appropriate action.”
The response to this effort has not been entirely positive. A January 2019 Kaiser Health News article noted that “Critics of the project call it a ‘witch hunt’ and an ‘inquisition.’ Many doctors said it is causing them or their peers to refuse patients’ legitimate requests for prescription painkillers out of fear their practices will come under disciplinary review.”
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee, this bill will result in DOJ costs of $874,000 in Fiscal Year (FY) 2019-20, $1.5 million in FY 2020-21, $1.0 million in FY 2021-22, and $496,000 in FY 2022-23 for up to six positions and consultant resources in anticipation of increase workload related to the expanded access and new physician and surgeon group. The analysis also notes that the CURES Fund would require a fee increase in the 2019-20 Budget year to an estimated $14 annually, from $6 annually, but could be reduced after 2020-21, after stabilization of expenditure patterns.
California Academy of Child and Adolescent Psychiatry
California Academy of Family Physicians
California Chapter of the American College of Emergency Physicians
California Chiropractic Association
California Dental Association
California Medical Association
California Narcotic Officers’ Association
California Radiological Society
California State Board of Pharmacy
California Veterinary Medical Association
Californiahealth+ Advocates
County Behavioral Health Directors Association
County of San Diego
Medical Board of California
Ochin, INC.
American Civil Liberties Union of California
Electronic Frontier Foundation
ARGUMENTS IN SUPPORT: According to the County of San Diego, “Misuse of prescription opioids contributes to the ongoing opioid epidemic and AB 528, by improving CURES reporting requirements from seven days to one working day, may help prevent misuse, addiction and overdose. Having access to real-time, up-to-date prescription information in CURES will help doctors and pharmacies quickly identify efforts to potentially misuse prescription medication.”
According to the California Medical Association, “Combatting California’s opioid crisis requires the utilization of all types of available resources, one of those critical components being the CURES system. The system, however, is only as effective as a resource as the data contained within it. Currently, pharmacists have up to seven days to update the CURES system after dispensing a controlled substance to a patient. Under AB 528, pharmacists would be required to update the system within one working day of dispensing a controlled substance to a patient. AB 528 also contains critical fixes to the “mandatory check” requirement for physicians of the CURES system. These fixes ensure that physicians avoid duplicative work, such as logging into the system multiple times within the same day for the same patient, allow for delegates to actually pull the patient record from CURES, which is saved in the medical record and currently accessed by the delegate anyways, and removes onerous administrative requirements that do not serve to protect patients, but add time to appointments and additional overall costs to the healthcare system.”
ARGUMENTS IN OPPOSITION: The American Civil Liberties Union of California is opposed to AB 528 unless it is amended. They argue that, “AB 528 would take large steps backwards in protecting the privacy of Californians’ medical information by expanding the list of prescription medications that must be tracked in CURES. Additionally, CURES may fall outside of the state and federal medical privacy statutes because neither the database itself nor the DOJ, which administers the CURES database, fall under any of the categories of entities that must keep medical information private, and thus these medical privacy laws may not provide privacy guarantees for the extremely sensitive information in CURES. By adding more prescriptions to CURES without addressing its privacy gaps, AB 528 would exempt from these privacy protections even more sensitive medical information for even more Californians.” The ACLU cites examples of sensitive information that could be exposed, such as prescription testosterone injections revealing a person is a transgender man, prescriptions for anti-anxiety medications revealing a mental illness diagnosis, or a prescription for Marinol indication a person may be fighting weight loss associated with HIV/AIDS. Additionally, the ACLU argues that the CURES database has existing privacy issues, thus its scope should not be expanded. They request amendments to add a warrant requirement to prevent various agencies from accessing personal information in CURES without probably cause and to delete the addition of schedule V drugs to the CURES database.
ASSEMBLY FLOOR: 77-0, 5/2/19
AYES: Aguiar-Curry, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
NO VOTE RECORDED: Arambula, Mullin, Quirk
Prepared by: Sarah Mason / B., P. & E.D. /
9/9/19 18:22:06
**** END ****
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 528 |
THIRD READING
Bill No: AB 528
Amended: 7/3/19 in Senate
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 8-0, 7/1/19
AYES: Glazer, Archuleta, Dodd, Galgiani, Hill, Leyva, Pan, Wilk
NO VOTE RECORDED: Chang
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/30/19
AYES: Portantino, Bates, Bradford, Durazo, Hill, Jones, Wieckowski
ASSEMBLY FLOOR: 77-0, 5/2/19 - See last page for vote
SUBJECT: Controlled substances: CURES database
DIGEST:
This bill adds Schedule V drugs to the Controlled Substances Utilization Review and Evaluation System (CURES); changes the required timeframe in which pharmacists are required to report dispensed prescriptions from seven days to the following business day; and makes other technical changes.
Existing law:
- Establishes CURES for the electronic monitoring of Schedule II, III and IV controlled substance prescriptions. CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the Department of Justice (DOJ) no more than seven days from the time prescriptions are dispensed. (HSC § 11165)
- States that the purpose of CURES is to assist law enforcement and regulatory agencies in controlling diversion and abuse of Schedule II, III and IV controlled substances and for statistical analysis, education and research. (HSC § 11165 (a))
- Establishes privacy protections for patient data and specifies that the operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations. (HSC §§ 11165 (c) (1), (c) (2) (A), and (c) (3))
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) registration providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Requires certain health care practitioners to consult the CURES database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC § 11165.4)
This bill:
- Expands the drugs required to be reported and monitored in CURES to include Schedule V controlled substances.
- Delays the requirement for DOJ to adopt regulations regarding the access and use of the information within CURES until January 2020.
- Changes the required timeframe in which dispensers are required to report dispensed prescriptions from seven days to one working day. Clarifies that veterinarians are not subject to this timeframe and authorized to report information as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed.
- Authorizes a licensed physician and surgeon who does not hold a DEA registration to submit an application to obtain approval to access CURES information.
- Clarifies patient activity report authority for individuals delegated by prescribers or dispensers to access information.
Background
Through the Controlled Substances Act of 1970, the federal government regulates the manufacture, distribution and dispensing of controlled substances. The act ranks into five schedules those drugs known to have potential for physical or psychological harm, based on three considerations: (1) their potential for abuse; (2) their accepted medical use; and, (3) their accepted safety under medical supervision. Schedule I controlled substances have a high potential for abuse and no generally accepted medical use such as heroin, ecstasy, and LSD; Schedule II controlled substances have a currently accepted medical use in treatment, or a currently accepted medical use with severe restrictions, and have a high potential for abuse and psychological or physical dependence. Schedule II drugs can be narcotics or non-narcotic. Examples of Schedule II controlled substances include combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), morphine, methadone, Ritalin, Demerol, Percocet, Percodan, fentanyl and Oxycontin; Schedule III and IV controlled substances have a currently accepted medical use in treatment, less potential for abuse but are known to be mixed in specific ways to achieve a narcotic-like end product. Examples include Tylenol with codeine, testosterone, Xanax, Ambien and other anti-anxiety drugs and; Schedule V drugs have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes.
With rising levels of prescription drug abuse, prescription drug monitoring programs (PDMPs) assist law enforcement and regulatory bodies with their efforts to reduce drug abuse and diversion. In California, CURES is an electronic tracking program that reports all pharmacy (and specified types of prescriber) dispensing of certain schedules of controlled drugs by drug name, quantity, prescriber, patient, and pharmacy. Data from CURES is managed by DOJ. Information tracked in CURES contains the patient name, prescriber name, pharmacy name, drug name, amount and dosage, and is available to law enforcement agencies, regulatory bodies, prescribers, dispensers, and qualified researchers. CURES provides information to identify if a person is “doctor shopping” (when a patient, often a prescription-drug addict, visits multiple doctors to obtain multiple prescriptions for drugs, or uses multiple pharmacies to obtain prescription drugs). The system can also report on the top drugs prescribed for a specific time period, drugs prescribed in a particular county, doctor prescribing data, pharmacy dispensing data, and is a critical tool for assessing whether multiple prescriptions for the same patient may exist.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists and other dispensers are required to report basic information about the patient and their prescription within seven days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Information in CURES is not available to just anyone. Data can only be accessed by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense Schedule II, Schedule III, and Schedule IV controlled substances; appropriate state, local and federal persons or public agencies for disciplinary, civil or criminal actions; other agencies or entities, as determined by DOJ, for educating practitioners and others, in lieu of disciplinary, civil or criminal actions and; non-identifying CURES data may be provided to public and private entities for education, research, peer review and statistical analysis
The question of whether a warrant should be required for searches of CURES has extended into investigations by regulatory boards for purposes of disciplinary actions against licensees. This practice has existed since the early iterations of the database, though SB 482 (Lara, Chapter 708, Statutes of 2016) expressly limited Department of Consumer Affairs investigator searches to regulatory boards whose licensees prescribe, order, administer, furnish, or dispense controlled substances.
In 2008, the Medical Board of California (MBC) began an investigation into Dr. Alwin Carl Lewis, a licensed physician who recommended a controversial diet in which patients were encouraged to eat two meals consisting of only five bites of food each day. As part of this inquiry, MBC investigators ran a search for Dr. Lewis in CURES to determine if he had misused his prescribing privileges in addition to offering questionable nutritional advice. The search resulted in MBC filing additional charges for overprescribing. Dr. Lewis immediately sought to have the overprescribing charges dismissed on the basis that because the allegations against him relating to his diet recommendations were irrelevant to his drug prescribing history, the MBC did not have good cause to conduct the CURES search without a warrant.
Years of litigation resulted from this dispute. Dr. Lewis’s objections to the CURES search were rejected by an administrative law judge, the Los Angeles County Superior Court, and the Court of Appeal, respectively. Eventually, the case was granted review by the Supreme Court of California in Lewis v. Superior Court. In its opinion issued in July of 2017, the Court ruled in favor of the MBC. The Court found that patients did indeed have a privacy interest in their prescription records, and that the MBC’s search encroached upon this interest. However, the Court held that “even assuming the Board's actions constituted a serious intrusion on a legally protected privacy interest, its review of these records was justified by the state’s dual interest in protecting the public from the unlawful use and diversion of a particularly dangerous class of prescription drugs and protecting patients from negligent or incompetent physicians.” The balancing test employed by the Court in Lewis reflects generally the priorities that must be weighed for any CURES policies invoking patient privacy rights.
The use of CURES data remains a sensitive issue. A Los Angeles Times series, “Dying For Relief,” highlighted the role of prescription drugs in overdose deaths as determined through the examination of coroners’ reports. Reporters conducted an analysis of coroners’ reports for over 3,000 deaths occurring in four counties (Los Angeles, Orange, Ventura and San Diego) where toxicology tests found a prescription drug in the deceased’s system, usually a painkiller, anti-anxiety drug or other narcotic; coroners’ investigators reported finding a container of the same medication bearing the doctor's name, or records of a prescription; the coroner determined that the drug caused or contributed to the death. The analysis found that in nearly half of the cases where prescription drug toxicity was listed as the cause of death, there was a direct connection to a prescribing physician. The Times created a database linking overdose deaths to the doctors who prescribed drugs, and found that more than 80 of the doctors whose names were listed on prescription bottles found at the home of or on the body of a decedent had been the prescribing physician for three or more dead patients. Their analysis found that one doctor was linked to as many as 16 dead patients.
Following the veto of 2013 legislation (SB 62, Lieu), which was introduced in response to the series, and that would have required coroners in California to report to the MBC when they receive information, based on findings that were reached by, or documented and approved by, a pathologist, indicating that the cause of death was due to a Schedule II, III, or IV drug, MBC entered into a data use agreement with the California Department of Public Health (CDPH) to receive death certificate data when the death was related to opioids. According to MBC’s 2017-2018 annual report, the “death certificate project” uses information from death records to identify physicians that may be inappropriately prescribing opioids to their patients. MBC has used information from CDPH to investigate licensees who may have violated the law and has reviewed CURES prescription information, leading to matches of patients and prescribers. According to MBC, “the Board understands that just because a patient death occurred, it does not automatically mean the physician deviated from the standard of care or violated the Medical Practice Act. However, in cases where the Board determines a violation occurred, the Board takes appropriate action.”
The response to this effort has not been entirely positive. A January 2019 Kaiser Health News article noted that “Critics of the project call it a ‘witch hunt’ and an ‘inquisition.’ Many doctors said it is causing them or their peers to refuse patients’ legitimate requests for prescription painkillers out of fear their practices will come under disciplinary review.”
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee, this bill will result in DOJ costs of $874,000 in Fiscal Year (FY) 2019-20, $1.5 million in FY 2020-21, $1.0 million in FY 2021-22, and $496,000 in FY 2022-23 for up to six positions and consultant resources in anticipation of increase workload related to the expanded access and new physician and surgeon group. The analysis also notes that the CURES Fund would require a fee increase in the 2019-20 Budget year to an estimated $14 annually, from $6 annually, but could be reduced after 2020-21, after stabilization of expenditure patterns.
California Academy of Child and Adolescent Psychiatry
California Academy of Family Physicians
California Chapter of the American College of Emergency Physicians
California Chiropractic Association
California Dental Association
California Medical Association
California Narcotic Officers’ Association
California Radiological Society
California State Board of Pharmacy
California Veterinary Medical Association
Californiahealth+ Advocates
County Behavioral Health Directors Association
County of San Diego
Medical Board of California
Ochin, INC.
OPPOSITION: (Verified 8/30/19)
American Civil Liberties Union of California
Electronic Frontier Foundation
ARGUMENTS IN SUPPORT: According to the County of San Diego, “Misuse of prescription opioids contributes to the ongoing opioid epidemic and AB 528, by improving CURES reporting requirements from seven days to one working day, may help prevent misuse, addiction and overdose. Having access to real-time, up-to-date prescription information in CURES will help doctors and pharmacies quickly identify efforts to potentially misuse prescription medication.”
According to the California Medical Association, “Combatting California’s opioid crisis requires the utilization of all types of available resources, one of those critical components being the CURES system. The system, however, is only as effective as a resource as the data contained within it. Currently, pharmacists have up to seven days to update the CURES system after dispensing a controlled substance to a patient. Under AB 528, pharmacists would be required to update the system within one working day of dispensing a controlled substance to a patient. AB 528 also contains critical fixes to the “mandatory check” requirement for physicians of the CURES system. These fixes ensure that physicians avoid duplicative work, such as logging into the system multiple times within the same day for the same patient, allow for delegates to actually pull the patient record from CURES, which is saved in the medical record and currently accessed by the delegate anyways, and removes onerous administrative requirements that do not serve to protect patients, but add time to appointments and additional overall costs to the healthcare system.”
ARGUMENTS IN OPPOSITION: The American Civil Liberties Union of California is opposed to AB 528 unless it is amended. They argue that, “AB 528 would take large steps backwards in protecting the privacy of Californians’ medical information by expanding the list of prescription medications that must be tracked in CURES. Additionally, CURES may fall outside of the state and federal medical privacy statutes because neither the database itself nor the DOJ, which administers the CURES database, fall under any of the categories of entities that must keep medical information private, and thus these medical privacy laws may not provide privacy guarantees for the extremely sensitive information in CURES. By adding more prescriptions to CURES without addressing its privacy gaps, AB 528 would exempt from these privacy protections even more sensitive medical information for even more Californians.” The ACLU cites examples of sensitive information that could be exposed, such as prescription testosterone injections revealing a person is a transgender man, prescriptions for anti-anxiety medications revealing a mental illness diagnosis, or a prescription for Marinol indication a person may be fighting weight loss associated with HIV/AIDS. Additionally, the ACLU argues that the CURES database has existing privacy issues, thus its scope should not be expanded. They request amendments to add a warrant requirement to prevent various agencies from accessing personal information in CURES without probably cause and to delete the addition of schedule V drugs to the CURES database.
ASSEMBLY FLOOR: 77-0, 5/2/19
AYES: Aguiar-Curry, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
NO VOTE RECORDED: Arambula, Mullin, Quirk
Prepared by: Sarah Mason / B., P. & E.D. /
9/1/19 14:11:41
**** END ****
SENATE COMMITTEE ON
Senator Anthony Portantino, Chair
2019 - 2020 Regular Session
AB 528 (Low) - Controlled substances: CURES database
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
Assembly Bill 528 would add Schedule V drugs to the Controlled Substances Review and Evaluation Systems (CURES); reduce, from seven days to the following business day, the timeframe a pharmacist must report a dispense prescription; extend by one year the date Department of Justice must adopt specified regulations; and make other technical changes.
Fiscal Impact:
- Department of Justice (DOJ): $874,000 in FY 2019-20, $1.5 million in FY 2020-21, $1.0 million in FY 2021-22, and $496,000 in FY 2022-23 for up to 6.0 positions and consultant resources in anticipation of increase workload related to the expanded access and new physician and surgeon group. Specifically:
- 2.0 permanent and 1.0 limited-term Program Technicians to assist new delegate users with the registration process and address anticipated increase calls to the CURES Help Desk.
- 1.0 permanent Staff Service Analyst to assist the Hawkins Data Center with system testing, update User Guides, and provide client support.
- 1.0 permanent and 1.0 limited-term Information Technology Specialists I to conduct procurements for consultant resources and provide project-specific testing and requirements.
- Consultant and contract resources to assist with the software development cycle and project approval lifecycle, and approximately $432,000 for California Department of Technology external project planning, oversight, and tracking.
- Department of Consumer Affairs (DCA): A current year budget appropriation and commensurate expenditure authority to reimburse the DOJ in 2019-20 for the amount in excess of the CURES Fund current expenditure amount of $3.9 million. The CURES Fund would require a fee increase in the 2019-20 budget year to an estimated $14 annually, from $6 annually, but could be reduced after 2020-21, after stabilization of expenditure patterns.
Background:
The federal Controlled Substances Act of 1970 regulates the manufacture, distribution and dispensing of controlled substances. The Act ranks, into five schedules, a drug’s potential for physical or psychological harm, accepted medical use, and accepted safety under medical supervision. Specifically:
- Schedule I controlled substances have a high potential for abuse and no generally accepted medical use. Examples include heroin, ecstasy, and LSD.
- Schedule II controlled substances have a currently accepted medical use in treatment, or a currently accepted medical use with severe restrictions, and a high potential for abuse and psychological or physical dependence. Schedule II drugs can be narcotics or non-narcotic. Examples include combination products with less than 15 mg of hydrocodone per dosage unit (Vicodin), morphine, methadone, Ritalin, Demerol, Percocet, fentanyl, and Oxycontin.
- Schedule III and IV controlled substances have a currently accepted medical treatment use, less potential for abuse, but are known to be mixed to achieve a narcotic-like end product. Examples include Tylenol with codeine, Xanax, Ambien, and other anti-anxiety drugs.
- Schedule V drugs have a low potential for abuse relative to substances listed in Schedule IV. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes.
Since 1939, California has had a form of prescription drug monitoring. California’s current prescription drug monitoring program is the CURES database, which electronically tracks all Schedule II – IV controlled substances dispensed to patients in California, with the intent of reducing prescription drug abuse and diversion. The reporting dispenser must create and upload the prescription record into CURES, and the DOJ manages the reported information. Authorized prescribers, pharmacists, law enforcement, and regulatory agencies can view information in CURES. Some of the information in the CURES system includes: patient name, date of birth, address; prescriber name; pharmacy name, license number; date prescription was dispensed; prescription number; drug name, quantity and strength; and number of refills remaining.
The system can also report on the top drugs prescribed for a specific time period, drugs prescribed in a particular county, doctor prescribing data, pharmacy dispensing data, and is a critical tool for assessing whether multiple prescriptions for the same patient may exist. Access to CURES is limited by a number of state and federal privacy laws, including HIPAA and CMIA. Data from CURES must only be provided to appropriate state, local, and federal persons, or public agencies for disciplinary, civil, or criminal purposes (HSC §11165(c)).
Since October 2, 2018, all health care practitioners must consult and review the CURES 2.0 system prior to prescribing, ordering, administering, or furnishing a Schedule II-IV controlled substance for the first time at least once every four months thereafter; if the medication remains part of the patient’s treatment plan. Prescribers will also be required to obtain and use tamper-resistant prescription forms ordered only from state-approved security printer.
Proposed Law:
- The bill would include the following provisions, among others:
- Changes the required timeframe in which pharmacists are required to report dispensed prescriptions from seven days to the following business day. Requires a veterinarian to report specified information to the DOJ as soon as reasonably possible but not more than seven days after the controlled substance is dispense.
- Delays, from July 1, 2020, to January 1, 2021, the requirement for the DOJ to adopt regulations regarding the access and use of information within CURES
- Removes the requirement that reports CURES include the International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available, and would require instead the most current ICD version, or any revision deemed sufficient by the Board of Pharmacy.
- Authorizes a licensed physician and surgeon who does not hold a DEA registration to submit an application to obtain approval to electronically access CURES. Upon approval, the DOJ must release to the physician and surgeon, or their delegate, the specified information.
- Makes other technical and conforming changes.
Related Legislation:
- SB 1240 (Stone, 2018) would have expended drugs required to be reported and monitored in CURES to include Schedule V controlled substances, among other information. The bill failed in the Senate Business and Professions Committee.
- AB 1752 (Low, 2018) would have added similar provisions to this bill. The bill was held on the Senate Appropriations Committee suspense file.
Staff Comments:
The Budget Act of 2019 includes $4.5 million for the CURES Fund, and after expenditures, would have a remaining fund balance of $427,000. The CURES fund is currently funded by $6 fee on prescribing licensees. The bill’s implementation costs appear to exceed the current fund balance. Staff notes a fee increase on licensees would need to occur to stabilize the fund.
More broadly, with respect to boards and bureaus’ fees to the Attorney General (AG) for serves as legal counsel and adjudication matters, on July 1, 2019, the Department of Justice (DOJ), Attorney General (AG) Office hourly rates increased, effective July 1, 2019. The new rates are:
- Attorney services from $170 to $220, resulting in a 30% increase
- Paralegal services from $120 to $205, resulting in a 71% increase.
The Budget Act of 2019 does not include this rate increase in DCA’s budget, so any budget augmentation for boards and bureaus would occur through the Joint Legislative Budget Committee notification. To the extent the bill would increase additional rates, there would be costs pressures on boards and bureaus for fee increases.
-- END --
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Steven Glazer, Chair
2019 - 2020 Regular
Bill No: AB 528 Hearing Date: July 1, 2019
Author: | Low | ||
Version: |
| ||
Urgency: | Fiscal: | ||
Consultant: | |||
Subject: Controlled substances: CURES database
SUMMARY: Adds Schedule V drugs to the Controlled Substances Utilization Review and Evaluation System (CURES); changes the required timeframe in which pharmacists are required to report dispensed prescriptions from seven days to the following business day; and makes other technical changes.
Existing law:
- Establishes various practice acts in the Business and Professions Code (BPC) governed by various boards within the Department of Consumer Affairs (DCA) which provide for the licensing and regulation of health care professionals including: physicians and surgeons (under the Medical Practice Act), dentists (under the Dental Practice Act), veterinarians (under the Veterinary Medicine Practice Act); registered nurses, nurse practitioners (NP) and certified nurse-midwives (CNM) (under the Nursing Practice Act); physician assistants (PA) (under the Physician Assistant Practice Act); osteopathic physicians and surgeons (under the Osteopathic Medical Practice Act); naturopathic doctors (ND) (under the Naturopathic Doctors Act); optometrists (under the Optometry Practice Act); doctors of podiatric medicine (under the Podiatric Act) and; pharmacies, pharmacists and wholesalers of dangerous drugs or devices (under the Pharmacy Law). (Business and Professions Code (BPC) §§ 500 et seq.)
- Defines “dispense” as the furnishing of drugs or devices upon a prescription from a physician, dentist, optometrist, podiatrist, veterinarian, or ND or upon an order to furnish drugs or transmit a prescription from a CNM, NP, PA, ND, or pharmacist acting within the scope of his or her practice. Dispense also means and refers to the furnishing of drugs or devices directly to a patient by a physician, dentist, optometrist, podiatrist, or veterinarian, or by a CNM, NP, ND, PA or pharmacist acting within the scope of his or her practice. (BPC § 4024)
- Specifies certain requirements regarding the dispensing and furnishing of dangerous drugs and devices, and prohibits a person from furnishing any dangerous drug or device except upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian or ND. (BPC § 4059)
- Establishes the Uniform Controlled Substances Act which regulates controlled substances and defines an opiate as any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. (Health and Safety Code (HSC) § 11020)
- Classifies controlled substances into five schedules according to their danger and potential for abuse. (HSC §§ 11054-11058)
- Prohibits any person other than a physician, dentist, podiatrist, veterinarian, ND (according to certain supervision and protocol requirements), pharmacist (according to certain authorization and according to certain policies and procedures), CNM (if furnished or ordered incidentally to the provision of family planning services, routine health care or perinatal care, or care rendered consistent with the CNM’s practice; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified), NP (if it is consistent with a NP’s educational preparation or for which clinical competency has been established and maintained; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified); a pharmacist or registered nurse or PA acting within the scope of an experimental health workforce project authorized by the Office of Statewide Health Planning and Development (HSC §§ 128125 et seq.); an optometrist licensed under the Optometry Practice Act, or an out-of-state prescriber acting in an emergency situation from writing or issuing a prescription for a controlled substance.
(HSC § 11150) - Establishes CURES for the electronic monitoring of Schedule II, III and IV controlled substance prescriptions. CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the Department of Justice (DOJ) no more than seven days from the time prescriptions are dispensed. (HSC § 11165)
- States that the purpose of CURES is to assist law enforcement and regulatory agencies in controlling diversion and abuse of Schedule II, III and IV controlled substances and for statistical analysis, education and research. (HSC § 11165 (a))
- Establishes privacy protections for patient data and specifies that the operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations. Specifies that CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Specifies that data obtained from CURES can only be accessed by appropriate state, local and federal persons or public agencies for disciplinary, civil or criminal actions. Specifies that CURES data shall also only be provided, as determined by DOJ, to other agencies or entities for educating practitioners and others, in lieu of disciplinary, civil or criminal actions. Authorizes non-identifying CURES data to be provided to public and private entities for education, research, peer review and statistical analysis. Requires DOJ, by July 2020, to adopt regulations regarding the access and use of the information within CURES, in consultation with stakeholders, that address the process for approving, denying, and disapproving individuals or entities seeking access to information in CURES; the purposes for which a health care practitioner may access information in CURES; the conditions under which a warrant, subpoena, or court order is required for a law enforcement agency to obtain information from CURES as part of a criminal investigation and; the process by which information in CURES may be provided for educational, peer review, statistical, or research purposes. (HSC §§ 11165 (c) (1), (c) (2) (A), and (c) (3))
- Requires DOJ to upgrade CURES to allow health information technology systems that meet certain patient privacy and data security requirements to interoperate with the database, allowing prescribers and dispensers to make queries through their electronic health record applications. (HSC § 11165.1)
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) registration providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Authorizes a health care practitioner to provide a patient with a copy of the patient’s CURES patient activity report as long as no additional CURES data is provided and authorizes a health care practitioner to keep a copy of the report in the patient’s medical record. (HSC § 11165 (c)(3))
- Requires certain health care practitioners to consult the CURES database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC § 11165.4)
- Establishes, pursuant to the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), certain requirements relating to the provision of health insurance, including provisions relating to the confidentiality of health records. HIPAA prohibits a covered entity that uses electronic means to perform HIPAA-covered transactions, from using or disclosing personal health information except pursuant to a written authorization signed by the patient or for treatment, payment, or health care operations. Notwithstanding those provisions, HIPAA allows a covered entity to maintain a directory of patients in its facility for specified purposes, and to disclose the protected health information of a patient to family members, relatives, or other persons identified by the patient, if certain conditions are met. Covered entities include health plans, health care clearinghouses, such as billing services and community health information systems, and health care providers that transmit health care data in a way that is regulated by HIPAA. HIPAA further provides that if its provisions conflict with a provision of state law, the provision that is most protective of patient privacy prevails. (Public Law 104–191, 104th Congress)
- Prohibits, pursuant to the state Confidentiality of Medical Information Act (CMIA), a provider of health care, a health care service plan, a contractor, a corporation and its subsidiaries and affiliates, or any business that offers software or hardware to consumers, including a mobile application or other related device, as defined, from intentionally sharing, selling, using for marketing, or otherwise using any medical information, as defined, for any purpose not necessary to provide health care services to a patient, except as expressly authorized by the patient, enrollee, or subscriber, as specified, or as otherwise required or authorized by law. A violation of the provisions of this act that results in economic loss or personal injury to a patient is a crime. (Civil Code Sections (CC) 56, et seq.)
- Defines, for purposes of the CMIA, “medical information” to mean “any individually identifiable information, in electronic or physical form, in possession of or derived from a provider of health care, health care service plan, pharmaceutical company, or contractor regarding a patient’s medical history, mental or physical condition, or treatment.” “Individually identifiable” means that the medical information includes or contains any element of personal identifying information sufficient to allow identification of the individual, such as the patient’s name, address, electronic mail address, telephone number, or social security number, or other information that, alone or in combination with other publicly available information, reveals the individual’s identity.” (CC § 56.05(g))
This bill:
- States Legislative intent that state laws regarding the operation and use of prescription drug monitoring programs continue to empower health care-oriented technology solutions to the opioid crisis.
- Expands the drugs required to be reported and monitored in CURES to include Schedule V controlled substances.
- Delays the requirement for DOJ to adopt regulations regarding the access and use of the information within CURES until January 2020.
- Adds the conditions under which an insurer providing workers’ compensation coverage may access information in CURES for purposes of reviewing a workers’ compensation claim, which shall at a minimum prohibit an insurer from using information obtained from the CURES database as the sole factor in evaluating a claim for approval or denial, to the issues that the regulations noted in 9) above must address.
- Changes the required timeframe in which dispensers are required to report dispensed prescriptions from seven days to one working day. Clarifies that veterinarians are not subject to this timeframe and authorized to report information as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed.
- Authorizes a licensed physician and surgeon who does not hold a DEA registration to submit an application to obtain approval to access CURES information.
- Clarifies patient activity report authority for individuals delegated by prescribers or dispensers to access information.
FISCAL EFFECT:
Unknown. This bill is keyed fiscal by Legislative Counsel.
COMMENTS:
- Purpose. The Author is the Sponsor of this bill. According to the Author, “Because prescriptions for Schedule V drugs have been deemed by the DEA to represent those regulated by the Controlled Substances Act with the lowest potential for abuse, an argument has been made that the state’s PDMP has no need to track them. However, assertions that Schedule V drugs like cough syrup with codeine are not susceptible to abuse or diversion were ultimately proven to be drastically misguided. Abuse of prescription-strength cough syrup containing codeine exploded as recreational use of the drug became popularized by hip-hop culture. Referred to through common slang terms like “purple drank,” “sizzurp,” “lean,” and “dirty sprite,” it has been widely reported that the theft of cough syrup containing codeine is one of the most prevalent causes for pharmacy break-ins.”
The Author states that “consistently requiring dispensers to report all Schedule V drugs is the most straightforwardly implementable way of expanding existing reporting requirements for pharmacies…Tracking the drugs in the database will significantly assist health professionals, regulators, and law enforcement in investigating cases of theft and abuse among these controlled substances.
“Reducing the amount of time provided to dispensers to report prescriptions to CURES from up to 7 days down to within the next business day will significantly improve the database’s reliability for practitioners seeking to identify multi-prescriber seeking behavior among their patients. The change would not substantially change current practice for the vast majority of pharmacies. It will, however, ensure that doctor shoppers are not able to take advantage of a time delay when seeking to obtain multiple prescriptions.”
“With the state’s PDMP query in place for thousands of physicians and other prescribers, a need has been identified to better integrate CURES data utilization within the clinical team environment. Empowering delegates with greater access to CURES will enable them to support physicians and streamline their review of patients’ prescription histories so that practitioners may incorporate that information more smoothly into their assessment of a patient’s needs.”
“Authorizing health care professionals to query CURES on behalf of workers compensation coverage providers will provide for additional safeguards against the abuse and diversion of prescription drugs, potentially saving patient lives by allowing for a more holistic understanding of a patient’s prescription history when controlled substances reimbursements are being approved.”
- Background.
Controlled Substances, PDMPs and CURES. Through the Controlled Substances Act of 1970, the federal government regulates the manufacture, distribution and dispensing of controlled substances. The act ranks into five schedules those drugs known to have potential for physical or psychological harm, based on three considerations: (a) their potential for abuse; (b) their accepted medical use; and,
(c) their accepted safety under medical supervision.
Schedule I controlled substances have a high potential for abuse and no generally accepted medical use such as heroin, ecstasy, and LSD.
Schedule II controlled substances have a currently accepted medical use in treatment, or a currently accepted medical use with severe restrictions, and have a high potential for abuse and psychological or physical dependence. Schedule II drugs can be narcotics or non-narcotic. Examples of Schedule II controlled substances include combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), morphine, methadone, Ritalin, Demerol, Percocet, Percodan, fentanyl and Oxycontin.
Schedule III and IV controlled substances have a currently accepted medical use in treatment, less potential for abuse but are known to be mixed in specific ways to achieve a narcotic-like end product. Examples include Tylenol with codeine, testosterone, Xanax, Ambien and other anti-anxiety drugs.
Schedule V drugs have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes.
With rising levels of prescription drug abuse, prescription drug monitoring programs (PDMPs) assist law enforcement and regulatory bodies with their efforts to reduce drug abuse and diversion. In California, CURES is an electronic tracking program that reports all pharmacy (and specified types of prescriber) dispensing of certain schedules of controlled drugs by drug name, quantity, prescriber, patient, and pharmacy. Data from CURES is managed by DOJ. Information tracked in CURES contains the patient name, prescriber name, pharmacy name, drug name, amount and dosage, and is available to law enforcement agencies, regulatory bodies, prescribers, dispensers, and qualified researchers. CURES provides information to identify if a person is “doctor shopping” (when a patient, often a prescription-drug addict, visits multiple doctors to obtain multiple prescriptions for drugs, or uses multiple pharmacies to obtain prescription drugs). The system can also report on the top drugs prescribed for a specific time period, drugs prescribed in a particular county, doctor prescribing data, pharmacy dispensing data, and is a critical tool for assessing whether multiple prescriptions for the same patient may exist.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists and other dispensers are required to report basic information about the patient and their prescription within 7 days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Over 50 million prescription records have been uploaded into the system by dispensers since the beginning of the CURES program. As of January 1, 2018, 170,422 users had been approved for access to the system. Last year, close to 10 million activity reports had been processed by practitioners, pharmacists, law enforcement, and regulatory users. The vast majority of these searches (over 99%) were queries made by prescribers and dispensers seeking to review a patient’s prescription history as a component of exercising informed clinical judgment before providing access to opioids or other controlled substances.
Health practitioners are required to consult the CURES database prior to writing a prescription for a Schedule II, III, or IV drug for the first time, and then at least once every four months as long as the prescription continues to be renewed. Other recently enacted statutes require the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements.
As attention to the opioid crisis continues to grow, CURES and other PDMPs are regularly mentioned as powerful tools for curbing the abuse of prescription drugs.
- PDMP Access. Information in CURES is not available to just anyone. Data can only be accessed by:
- A health care practitioner authorized to prescribe, order, administer, furnish, or dispense Schedule II, Schedule III, and Schedule IV controlled substances;
- Appropriate state, local and federal persons or public agencies for disciplinary, civil or criminal actions;
- Other agencies or entities, as determined by DOJ, for educating practitioners and others, in lieu of disciplinary, civil or criminal actions; and
- Non-identifying CURES data may be provided to public and private entities for education, research, peer review and statistical analysis
The question of whether a warrant should be required for searches of CURES has extended into investigations by regulatory boards for purposes of disciplinary actions against licensees. This practice has existed since the early iterations of the database, though SB 482 (Lara, Chapter 708, Statutes of 2016) expressly limited DCA investigator searches to regulatory boards whose licensees prescribe, order, administer, furnish, or dispense controlled substances. Each month, DCA investigators run hundreds of activity reports – still a very small relative portion of overall user activity – to determine whether prescribers and other licensees are misusing their professional privileges. Regulatory user activity is virtually unfettered and does not always result in the same type of auditable logging that other users incur when searching the system.
In 2008, the Medical Board of California (MBC) began an investigation into Dr. Alwin Carl Lewis, a licensed physician who recommended a controversial diet in which patients were encouraged to eat two meals consisting of only five bites of food each day. As part of this inquiry, MBC investigators ran a search for Dr. Lewis in CURES to determine if he had misused his prescribing privileges in addition to offering questionable nutritional advice. The search resulted in MBC filing additional charges for overprescribing. Dr. Lewis immediately sought to have the overprescribing charges dismissed on the basis that because the allegations against him relating to his diet recommendations were irrelevant to his drug prescribing history, the MBC did not have good cause to conduct the CURES search without a warrant.
Years of litigation resulted from this dispute. Dr. Lewis’s objections to the CURES search were rejected by an administrative law judge, the Los Angeles County Superior Court, and the Court of Appeal, respectively. Eventually, the case was granted review by the Supreme Court of California in Lewis v. Superior Court. The Court conducted a thorough analysis of the Legislature’s intent in creating CURES, the privacy rights implicated by searches of the system, and whether the MBC had violated any state or federal protections in its use of the database to investigate Dr. Lewis.
In its opinion issued in July of 2017, the Court ruled in favor of the MBC. The Court found that patients did indeed have a privacy interest in their prescription records, and that the MBC’s search encroached upon this interest. However, the Court held that “even assuming the Board's actions constituted a serious intrusion on a legally protected privacy interest, its review of these records was justified by the state’s dual interest in protecting the public from the unlawful use and diversion of a particularly dangerous class of prescription drugs and protecting patients from negligent or incompetent physicians.” The balancing test employed by the Court in Lewis reflects generally the priorities that must be weighed for any CURES policies invoking patient privacy rights.
The use of CURES data remains a sensitive issue. A Los Angeles Times series, “Dying For Relief,” highlighted the role of prescription drugs in overdose deaths as determined through the examination of coroners’ reports. Reporters conducted an analysis of coroners’ reports for over 3000 deaths occurring in four counties (Los Angeles, Orange, Ventura and San Diego) where toxicology tests found a prescription drug in the deceased’s system, usually a painkiller, anti-anxiety drug or other narcotic; coroners’ investigators reported finding a container of the same medication bearing the doctor's name, or records of a prescription; the coroner determined that the drug caused or contributed to the death. The analysis found that in nearly half of the cases where prescription drug toxicity was listed as the cause of death, there was a direct connection to a prescribing physician. The Times created a database linking overdose deaths to the doctors who prescribed drugs, and found that more than 80 of the doctors whose names were listed on prescription bottles found at the home of or on the body of a decedent had been the prescribing physician for 3 or more dead patients. Their analysis found that one doctor was linked to as many as 16 dead patients.
Following the veto of 2013 legislation (SB 62, Lieu), which was introduced in response to the series, and that would have required coroners in California to report to the Medical Board of California (MBC) when they receive information, based on findings that were reached by, or documented and approved by, a pathologist, indicating that the cause of death was due to a Schedule II, III, or IV drug, MBC entered into a data use agreement with the California Department of Public Health (CDPH) to receive death certificate data when the death was related to opioids. According to MBC’s 2017-2018 annual report, the “death certificate project” uses information from death records to identify physicians that may be inappropriately prescribing opioids to their patients. MBC has used information from CDPH to investigate licensees who may have violated the law and has reviewed CURES prescription information, leading to matches of patients and prescribers. According to MBC, “the Board understands that just because a patient death occurred, it does not automatically mean the physician deviated from the standard of care or violated the Medical Practice Act. However, in cases where the Board determines a violation occurred, the Board takes appropriate action.”
The response to this effort has not been entirely positive. A January 2019 Kaiser Health News article noted that “Critics of the project call it a ‘witch hunt’ and an ‘inquisition.’ Many doctors said it is causing them or their peers to refuse patients’ legitimate requests for prescription painkillers out of fear their practices will come under disciplinary review.”
- Related Legislation This Year. AB 149 (Cooper, Chapter 4, Statutes of 2019) clarifies the specifications for the uniquely serialized number required in the printing of new prescription forms by security printers approved by the DOJ.
AB 714 (Wood) would clarify current law requiring prescribers to offer a prescription for naloxone hydrochloride (NH) by specifying that the requirement only applies when an opioid or benzodiazepine is prescribed and exempts patients in inpatient facilities and patients who are terminally ill from having to receive the NH prescription and education on overdose prevention. (Status: This measure is currently pending in the Senate Committee on Appropriations.)
- Prior Related Legislation. CURES has been the focus of ongoing discussions in the Legislature, as California and the nation face an epidemic of prescription drug abuse and related overdose deaths.
SB 1240 (Stone) of 2018 would have expanded the drugs required to be reported and monitored in CURES to include all dangerous drugs and Schedule V controlled substances and would have required inclusion of a description of the diagnosis, condition, or purpose for which the prescription was issued and the directions for use to the list of information pharmacies are required to report to CURES for each prescription. (Status: This bill died in the Senate Committee on Business and Professions.)
AB 1751 (Low, Chapter 478, Statutes of 2018) provided a framework for CURES to connect with other states that comply with California’s patient privacy and data security standards.
AB 1752 (Low) of 2018 included the provisions of this bill related to Schedule V controlled substances. (Status: The measure was held under submission in the Senate Committee on Appropriations.)
AB 1753 (Low, Chapter 479, Statutes of 2018) would limit the number of security printers authorized to manufacture prescription pads and linking uniquely serialized pads with CURES.
AB 2086 (Gallagher, Chapter 274, Statutes of 2018) would allow prescribers of controlled substances to review a list of patients for whom they are listed as being the prescriber.
AB 40 (Santiago, Chapter 607, Statutes of 2017) authorized an entity that operates a health information technology system to establish an integration with, and submit queries to CURES, on either a user-initiated basis or automated basis, according to certain requirements.
SB 641 (Lara) of 2016 would have prohibited the DOJ from releasing data in CURES to a law enforcement agency except pursuant to a warrant. (Status: The measure did not move from the Assembly Committee on Public Safety.)
SB 482 (Lara, Chapter 708, Statutes of 2016) required a health care provider authorized to prescribe, order, administer, or furnish a controlled substance to consult CURES prior to prescribing a Schedule II, III or IV drug to a patient for the first time and at least once every four months thereafter if the substance remains part of the patient’s treatment. The bill provided exemptions from the responsibility to consult the CURES system, including while a patient is admitted to a certain type of facility, if a patient receives a non-refillable five-day supply or less prescription in conjunction with a surgery, and in the event of a technological failure or inability to access the CURES system.
SB 1258 (DeSaulnier) of 2014 would have made several changes to the ways that controlled substances are prescribed and tracked in the CURES and would have required medical providers to use electronic prescribing systems, would have required additional reporting of controlled substance prescribing, and would have placed additional restrictions on the prescribing of controlled substances.
(Status: The bill was held in the Senate Committee on Appropriations.)
SB 809 (De Saulnier, Chapter 400, Statutes of 2013) established a funding mechanism to update and maintain CURES, required all prescribing health care practitioners to apply to access CURES information, and established processes and procedures for regulating prescribing licensees through CURES and securing private information.
SB 151 (Burton, Chapter 406, Statutes of 2003) made the CURES program permanent.
AB 2655 (Matthews, Chapter 345, Statutes of 2002) extended the CURES program to 2008 and provided access to CURES data by licensed health care providers.
SB 1308 (Committee on Business and Professions, Chapter 655, Statutes of 1999) extended the sunset date on the CURES program to July 1, 2003 and required DOJ to submit annual status reports on the program to the Legislature.
AB 3042 (Takasugi, Chapter 738, Statutes of 1996) established a three year pilot program, beginning in July 1997, for the electronic monitoring of prescribing and dispensing of Schedule II controlled substances.
- Arguments in Support. According to the County of San Diego, “Misuse of prescription opioids contributes to the ongoing opioid epidemic and AB 528, by improving CURES reporting requirements from seven days to one working day, may help prevent misuse, addiction and overdose. Having access to real-time, up-to-date prescription information in CURES will help doctors and pharmacies quickly identify efforts to potentially misuse prescription medication.”
According to the California Medical Association, “Combatting California’s opioid crisis requires the utilization of all types of available resources, one of those critical components being the CURES system. The system, however, is only as effective as a resource as the data contained within it. Currently, pharmacists have up to seven days to update the CURES system after dispensing a controlled substance to a patient. Under AB 528, pharmacists would be required to update the system within one working day of dispensing a controlled substance to a patient. AB 528 also contains critical fixes to the “mandatory check” requirement for physicians of the CURES system. These fixes ensure that physicians avoid duplicative work, such as logging into the system multiple times within the same day for the same patient, allow for delegates to actually pull the patient record from CURES, which is saved in the medical record and currently accessed by the delegate anyways, and removes onerous administrative requirements that do not serve to protect patients, but add time to appointments and additional overall costs to the healthcare system.”
The California Pharmacists Association (CPhA) supports this bill if it is amended. According to CPhA, “we are compelled to clarify how [CURES] works and the current inability to meet the objectives of the sponsors for immediate accessibility of information entered into CURES. The current system is not readily available to a dispensing pharmacy or capable of providing information entered into CURES data process available immediately. Information entered in the system requires the following steps:
“1. A pharmacist must enter the information into the CURES system data repository for scrubbing or reformatting.
“2. The information then goes through Atlantic Associates, Inc., a contracted prescription collection and data processing and analytics service. While prescribers and pharmacists have an NPI (National Provider Identifier) numbers, patients have no unique or universal identifiers. Atlantic Associates uses the patient information from the prescription entered into the CURES Data base and uses an established algorithm to identify the patient for whom the prescription was dispensed. This process uses various data elements to attempt to identify a patient so that all relevant data is aggregated to the appropriate patient. There are numerous potential ways that the ability of the system to correctly identify the patient can be negatively impacted. This process generally takes multiple days.
“3. Upon completion of the process, Atlantic Associates then uploads the information into the CURES system. Based on this process there is functional “real time” information available in the data base.
“Today, this system requires the transmission of the information outside of the normal business processes of a pharmacy and does not allow a physician to review the data as part of their normal chart review process when examining a patient.
“While we support the goals of the bill, CPhA strongly objects to the inclusion of health plans access to the CURES system. CURES was not developed as a means for insurance companies to access patient’s personal information for purposes of claims review. We believe this will reverse years of progress in protecting the privacy of Californians’ medical information by allowing health plans to access this privileged information. CPhA respectfully requests an amendment to strike this language from the bill.”
- Arguments in Opposition. The American Civil Liberties Union of California is opposed to AB 528 unless it is amended. They argue that, “AB 528 would take large steps backwards in protecting the privacy of Californians’ medical information by expanding the list of prescription medications that must be tracked in CURES. Additionally, CURES may fall outside of the state and federal medical privacy statutes because neither the database itself nor the DOJ, which administers the CURES database, fall under any of the categories of entities that must keep medical information private, and thus these medical privacy laws may not provide privacy guarantees for the extremely sensitive information in CURES. By adding more prescriptions to CURES without addressing its privacy gaps, AB 528 would exempt from these privacy protections even more sensitive medical information for even more Californians.” The ACLU cites examples of sensitive information that could be exposed, such as prescription testosterone injections revealing a person is a transgender man, prescriptions for anti-anxiety medications revealing a mental illness diagnosis, or a prescription for Marinol indication a person may be fighting weight loss associated with HIV/AIDS.
Additionally, the ACLU argues that the CURES database has existing privacy issues, thus its scope should not be expanded. They request amendments to add a warrant requirement to prevent various agencies from accessing personal information in CURES without probably cause and to delete the addition of schedule V drugs to the CURES database.
The California Dental Association is also in opposition to AB 528 unless it is amended. They argue that “Allowing workers’ compensation companies to access the CURES database will do nothing to prevent opioid abuse, as claim denials will only determine whether a patient will need to pay out of pocket for a prescription and not whether the patient will be able to access the prescription. A workers’ compensation company, if given access to CURES, will be able to review a patients’ prescription history out of context and is irrelevant to the incident of care on which the claim is based….
“Permitting workers’ compensation companies to determine whether a prescription for a controlled substance is inappropriate significantly changes the scope and purpose of the CURES system.”
- Policy Questions and Suggested Amendments.
What is the rationale for authorizing physicians and surgeons who do not hold a DEA registration to have access to CURES? CURES requirements and access privileges apply to a number of health care professionals who have the authority to prescribe and dispense controlled substances. Regulatory boards also use information from CURES to determine, pursuant to an investigation, whether prescriptions were issued and dispensed in accordance with the law and according to the standard of care for a specific profession. It would be helpful for the Committee to better understand the rationale for the changes proposed in this bill authorizing access to non-DEA authorized prescribers, as well as how DOJ will be able to determine whether a physician or surgeon is accessing information about “a patient under their care” as the bill allows. AB 2086 (Gallagher, Chapter 274, Statutes of 2018) already authorized a prescriber of controlled substances to review a list of patients for whom they are listed as being the prescriber in order to provide all prescribers, not just physician and surgeon prescribers, with the ability to have a clear picture of their patients’ controlled substance prescription history. Given that it is not clear how consumers, patients, and the public will benefit from authorizing “a licensed physician and surgeon who does not hold a DEA registration” to “electronically access information regarding the controlled substance history of the patient”, and given that the provision only applies to physicians and surgeons while there are many other licensed health professionals with prescribing authority, the Author should continue to work with interested parties to determine the potential impacts stemming from this change and to provide a clear rationale for this new authority and this expanded CURES access.
CURES access to private third-parties. By requiring the AG to address “The conditions under which an insurer providing workers’ compensation coverage may access information in CURES for purposes of reviewing a workers’ compensation claim…”, this bill establishes a new precedent for access to CURES. Many entities have desired similar access, including pharmaceutical manufacturers seeking to have clearer information about prescriptions for their manufacturers. Given the significance of the potential implications to provide CURES access to private third parties, the bill should be amended to strike this authority according to the following:
On page 5, strike lines 7-10 inclusive.
The conditions under which an insurer providing workers’ line 8 compensation coverage may access information in CURES for line 9 purposes of reviewing a workers’ compensation claim, which shall line 10 at a minimum prohibit an insurer from using information obtained line 11 from the CURES database as the sole factor in evaluating a claim line 12 for approval or denial.
SUPPORT AND OPPOSITION:
Support:
American Property Casualty Insurance Association
California Academy of Child and Adolescent Psychiatry
California Academy of Family Physicians
California Chapter of the American College of Emergency Physicians
California Chiropractic Association
California Medical Association
California Narcotic Officers’ Association
California Radiological Society
California Pharmacists Association
California State Board of Pharmacy
California Veterinary Medical Association
County Behavioral Health Directors Association
County of San Diego
Medical Board of California
Zenith Insurance Company
Opposition:
American Civil Liberties Union of California
California Dental Association
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 528
Author:(Low)
As Introduced Ver:February 13, 2019
2/3 vote. Urgency
SUMMARY:
Changes the required timeframe in which pharmacists are required to report dispensed prescriptions to the state's prescription drug monitoring program (PDMP) from seven days to the following business day.
COMMENTS:
Currently, statute requires dispensers to report new prescriptions to the Department of Justice's PDMP, the Controlled Substances Utilization Review and Evaluation System (CURES), "as soon as reasonably possible, but not more than seven days." This means while data in the CURES 2.0 system is "real-time" in that reported prescriptions immediately appear in the database, for up to one week a dispensed prescription may not be appear in users' queries. Meanwhile, "doctor shoppers" are able to visit multiple prescribers to obtain prescriptions.
The majority of pharmacies in California do not report prescriptions directly into CURES. Atlantic Associates, a technology vendor, operates a Direct Dispense Application that facilitates reports between pharmacists and CURES. This application typically collects all Schedule II-IV prescriptions dispensed by the pharmacy each day and uploads them all into CURES overnight in a single batch process. The standard turnaround time for these uploads is within one day. While some pharmacies with smaller numbers of daily prescriptions manually upload files to CURES, this process is nearly universal for most prescriptions dispensed within the state.
Reducing the amount of time provided to dispensers to report prescriptions to CURES from up to seven days down to within the next business day will significantly improve the database's reliability for practitioners seeking to identify multi-prescriber seeking behavior among their patients. The change would not substantially change current practice for the vast majority of pharmacies. It will, however, ensure that doctor shoppers are not able to take advantage of a time delay when seeking to obtain multiple prescriptions.
According to the Author:
"PDMPs are recognized by experts as a powerful tool to combat the abuse and diversion of prescription drugs like opioids. Data reported to CURES provides health professionals, regulators, and law enforcement with critical information to promote safe prescribing and identify abuse. AB 528 improves these reports. Reducing the time a pharmacist has to report to CURES from seven days to one working day prevents "doctor shoppers" from visiting multiple prescribers over the course of a whole week to obtain multiple prescriptions. With this bill, CURES will function even better to help combat the opioid crisis."
Arguments in Support:
The California Medical Association (CMA) supports the bill. The CMA states that "In order for a physician to make the most informed decision when prescribing a controlled substance to a patient, they must know what medication the patient is currently taking. This bill would ensure that the physician has up-to-date information on any controlled substances a patient is taking to within one day of dispensing. This information is critically important to both the physician and the safety of the patient."
Arguments in Opposition:
None on file.
FISCAL COMMENTS:
According to the Assembly Appropriations Committee, minor and absorbable costs to the Board of Pharmacy (Pharmacy Board Contingent Fund).
VOTES:
ASM BUSINESS AND PROFESSIONS: 19-0-1
YES: Low, Brough, Bloom, Chen, Chiu, Cunningham, Dahle, Eggman, Fong, Gipson, Gloria, Grayson, Holden, Irwin, McCarty, Medina, Mullin, Ting, Wood
ABS, ABST OR NV: Obernolte
ASM APPROPRIATIONS: 18-0-0
YES: Gonzalez, Bigelow, Bloom, Bonta, Brough, Calderon, Carrillo, Chau, Diep, Eggman, Fong, Gabriel, Jones-Sawyer, Maienschein, Obernolte, Petrie-Norris, Quirk, Robert Rivas
UPDATED:
VERSION: February 13, 2019
CONSULTANT: Robert Sumner / B. & P. / (916) 319-3301 FN: 0000269
Date of Hearing: April 24, 2019
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 528
Author:(Low) – As Introduced Ver:February 13, 2019
Policy Committee: | Business and Professions | Vote: | 19 - 0 |
Urgency: Yes State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill changes the required timeframe in which pharmacists are required to report dispensed prescriptions to the state’s prescription drug monitoring program, from seven days to the following business day.
FISCAL EFFECT:
Minor and absorbable costs to the Board of Pharmacy (Pharmacy Board Contingent Fund).
COMMENTS:
- Purpose. This bill improves the timeliness of reporting to the CURES system, the state’s prescription drug monitoring program, to ensure delays do not hide critical information about dispensed prescriptions. Reducing the time a pharmacist has to report to CURES from seven days to one working day prevents "doctor shoppers" from visiting multiple prescribers over the course of a week to obtain multiple prescriptions.
- Background. Under current law, the DOJ manages CURES, a system used to track prescriptions of Schedule II, III and IV drugs—generally, drugs accepted for medical use with moderate to significant potential for addiction or abuse. Pharmacists are required to submit information to CURES within seven days of dispensing prescription for any of these drugs. Prescribers, law enforcement personnel and regulatory agencies are authorized to access CURES. For example, a physician can access CURES to review whether a patient has already been prescribed controlled substances before issuing a new prescription.
Most pharmacies already comply with the one-day reporting requirement through the use of a vendor that collects and uploads all pharmacy data in a batch process daily.
- Prior Legislation. AB 1752 (Low), of the 2017-18 Legislative Session, would have reduced the required timeframe in which pharmacists are required to report dispensed prescriptions to CURES from seven days to the following business day and would have added Schedule V drugs to CURES. AB 1752 was held on the Suspense File of the Senate Appropriations Committee.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing:
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 528
Author:(Low) – As Introduced Ver:February 13, 2019
SUBJECT: Controlled substances: CURES database.
SUMMARY: Changes the required timeframe in which pharmacists are required to report dispensed prescriptions to the state’s prescription drug monitoring program (PDMP) from seven days to the following business day.
EXISTING LAW:
- Allows only a physician, dentist, podiatrist, veterinarian, naturopathic doctor, registered nurse, certified nurse-midwife, optometrist, or out-of-state prescriber to write or issue a prescription. (Health and Safety Code (HSC) § 11150)
- States that a prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice, and that the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. (HSC § 11153)
- Prohibits medical professionals from prescribing, administering, or dispensing a controlled substance to an addict, as defined. (HSC § 11156)
- Establishes the Controlled Substance Utilization Review and Evaluation System (CURES), a PDMP maintained by the California Department of Justice (DOJ) for the purposes of collecting records of dispensed controlled substances for review by licensed prescribers and dispensers, regulatory investigators, law enforcement, and statistical researchers. (HSC § 11165(a))
- Requires pharmacists and other dispensers to report information to CURES within 7 days relating to prescriptions of Schedule II, III, and IV controlled substances. (HSC § 11165(d))
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) registration providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Requires certain health care practitioners to consult the CURES database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC § 11165.4)
- Requires the DOJ to upgrade CURES to allow health information technology systems that meet certain patient privacy and data security requirements to interoperate with the database, allowing prescribers and dispensers to make queries through their electronic health record applications. (HSC § 11165.1)
- Prohibits any person from obtaining or attempting to obtain a prescription for controlled substances, by fraud, deceit, misrepresentation, subterfuge, or the concealment of a material fact. (HSC § 11173)
- Enables security printers and prescribers to report stolen or lost prescription pads to the DOJ through CURES. (HSC § 11165.3)
- Provides dedicated funding for the CURES program through an annual license fee of $6 assessed for licensees authorized to prescribe or dispense controlled substances in California. (Business and Professions Code (BPC) § 208)
- Authorizes the DOJ to seek voluntarily contributed private funds from insurers, health care service plans, qualified manufacturers, and other donors for the purpose of supporting CURES. (HSC § 11165.5)
- Allows the DOJ to conduct audits of CURES and its users and issue citations and fines for system misuse. (HSC § 11165.2)
- Requires the CURES database to comply with all applicable federal and state privacy and security laws and regulations and requires the DOJ to establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES. (HSC § 11165(c))
THIS BILL:
- Requires dispensers to report prescription information to CURES within one working day.
- States that it is the intent of the Legislature that state laws regarding the operation and use of prescription drug monitoring programs continue to empower health care-oriented technology solutions to the opioid crisis.
FISCAL EFFECT: Unknown; this bill is keyed fiscal by the Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author:
PDMPs are recognized by experts as a powerful tool to combat the abuse and diversion of prescription drugs like opioids. Data reported to CURES provides health professionals, regulators, and law enforcement with critical information to promote safe prescribing and identify abuse. AB 528 improves these reports. Reducing the time a pharmacist has to report to CURES from 7 days to one working day prevents “doctor shoppers” from visiting multiple prescribers over the course of a whole week to obtain multiple prescriptions. With this bill, CURES will function even better to help combat the opioid crisis.
Background.
Overview of the Opioid Crisis. In October of 2017, the White House declared the opioid crisis a public health emergency, formally recognizing what had long been understood to be a growing epidemic responsible for devastation in communities across the country. According to the Centers for Disease Control and Prevention, as many as 50,000 Americans died of an opioid overdose in 2016, representing a 28 percent increase over the previous year. Additionally, the number of Americans who died of an overdose of fentanyl and other opioids more than doubled during that time with nearly 20,000 deaths. These death rates compare to, and potentially exceed, those at the height of the AIDS epidemic.
Opioids are a class of drugs prescribed and administered by health professionals to manage pain. Modern use of the term “opioid” typically describes both naturally occurring opiates derived from the opium poppy as well as their manufactured synthetics. Common examples of prescription opioids include oxycodone (OxyContin, Percocet); hydrocodone (Vicodin, Norco, Lorcet); codeine; morphine; and fentanyl. Heroin is also an opioid.
In addition to providing pain relief, opioids can be used as a cough suppressant, an antidiarrheal, a method of sedation, and a treatment for shortness of breath. The majority of pharmaceutical opioids are Schedule II drugs under the federal Controlled Substances Act, considered by the federal Drug Enforcement Agency (DEA) to have a high potential for abuse that may lead to severe psychological or physical dependence. However, combination drugs containing lower doses of opioids combined with other active ingredients are typically less restricted; for example, cough syrups containing low doses of codeine are frequently classified Schedule V medications.
The abuse of prescription drugs was historically viewed as a criminal concern analogous to street narcotics cases regularly investigated by law enforcement. In recent years, however, an expert consensus has evolved around the opinion that the opioid crisis must be addressed through the lens of public health policy. This belief is supported by research demonstrating how health professionals may have inadvertently contributed to the origins of the crisis. It is widely accepted that health professionals will play a necessarily critical role in any meaningful solutions.
In the opioid crisis’s broader national context, there has been a persistent perception that California represents a relatively minor segment of an epidemic more typically identified with states like New Hampshire and West Virginia. However, there is substantial evidence that communities in California have been much harder hit than may be generally believed. For example, in 2015, several rural counties in California saw as many or more drug overdose deaths per 100,000 residents than some Midwestern states. It has been reported than some small counties had more opioid prescriptions than residents. In total, the California Department of Public Health estimates that nearly 2,000 Californians died of an opioid overdose in 2016.
In February of 2018, a bipartisan coalition of California State Assemblymembers announced a package of legislation aimed at combating the opioid crisis. The bills have been presented as representing a diversity of approaches to curbing overprescription, encouraging treatment, and preventing diversion. The potential of each proposed measure to effectively address the epidemic of prescription drug abuse must be evaluated in proportion to any added burden to those health professionals who remain tasked with ensuring that legitimate treatment continues to be provided to patients with pain management needs.
CURES Database. CURES was first established in 1996 as a “technologically sophisticated” database containing prescription records collected through California’s Triplicate Prescription Program, which provided the DOJ with copies of all Schedule II drug prescriptions. Subsequent legislation made CURES the state’s sole prescription record repository and added Schedule III and IV drugs to the database. In 2008, CURES was upgraded to function as a PDMP, allowing health professionals, regulators, and law enforcement to conduct web-based searches of the system to inform prescribing practices and support investigations.
Budget problems later plagued the database as the elimination of the DOJ’s Bureau of Narcotics Enforcement effectively defunded the CURES program. Users of the system complained that the PDMP offered insufficient client support and was plagued with technical issues. In response, Attorney General Kamala D. Harris sponsored legislation to overhaul the database with revenue newly derived from a $6 license fee for healing arts professionals. The resulting system, commonly referred to as “CURES 2.0,” is considered to be a significantly improved, state-of-the-art tool for addressing the abuse and diversion of opioids and other prescription drugs.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists are required to report basic information about the patient and their prescription within 7 days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Over 50 million prescription records have been uploaded into the system by dispensing pharmacists since the beginning of the CURES program. As of January 1, 2018, 170,422 users had been approved for access to the system. Last year, close to 10 million activity reports had been processed by practitioners, pharmacists, law enforcement, and regulatory users. The vast majority of these searches (over 99%) were queries made by prescribers and dispensers seeking to review a patient’s prescription history as a component of exercising informed clinical judgment before providing access to opioids or other controlled substances.
Access to CURES is limited by a number of state and federal privacy laws. This includes the Health Insurance Portability and Accountability Act (HIPAA), the California Medical Information Act, and the Information Practices Act. Whether law enforcement use of the system implicates the Fourth Amendment’s protections against unreasonable searches remains a topic of debate. In 2017, the Supreme Court of California ruled in Lewis v. Superior Court that privacy interests are justified by the state’s interest in preventing drug diversion and protecting patients.
As of October 2018, health practitioners are required to consult the CURES database prior to writing a prescription for a Schedule II, III, or IV drug for the first time, and then at least once every four months as long as the prescription continues to be renewed. Other recently enacted statutes require the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements. As attention to the opioid crisis continues to grow, CURES and other PDMPs are regularly mentioned as powerful tools for curbing the abuse of prescription drugs.
CURES Reporting Timelines. Currently, statute requires dispensers to report new prescriptions to CURES “as soon as reasonably possible, but not more than seven days.” This means while data in the CURES 2.0 system is “real-time” in that reported prescriptions immediately appear in the database, for up to one week a dispensed prescription may not be appear in users’ queries. Meanwhile, “doctor shoppers” are able to visit multiple prescribers to obtain prescriptions.
The majority of pharmacies in California do not report prescriptions directly into CURES. Atlantic Associates, a technology vendor, operates a Direct Dispense Application that facilitates reports between pharmacists and CURES. This application typically collects all Schedule II-IV prescriptions dispensed by the pharmacy each day and uploads them all into CURES overnight in a single batch process. The standard turnaround time for these uploads is within one day. While some pharmacies with smaller numbers of daily prescriptions manually upload files to CURES, this process is nearly universal for most prescriptions dispensed within the state.
Reducing the amount of time provided to dispensers to report prescriptions to CURES from up to 7 days down to within the next business day will significantly improve the database’s reliability for practitioners seeking to identify multi-prescriber seeking behavior among their patients. The change would not substantially change current practice for the vast majority of pharmacies. It will, however, ensure that doctor shoppers are not able to take advantage of a time delay when seeking to obtain multiple prescriptions.
Current Related Legislation. AB 387 (Gabriel) would require a physician and surgeon to indicate the purpose for a drug or device on the prescription for that drug or device when providing a prescription to a patient unless the patient chooses to opt out of having the purpose for the drug or device included on the prescription. This bill is pending in the Assembly Business and Professions Committee.
Prior Related Legislation. AB 1751 (Low, Chapter 478, Statutes of 2018) provides a framework for the CURES PDMP to connect with other states that comply with California’s patient privacy and data security standards.
AB 1752 (Low) would have reduced the required timeframe in which pharmacists are required to report dispensed prescriptions to CURES from seven days to the following business day and would have added Schedule V drugs to CURES. This bill was held under submission on the Senate Appropriations suspense file.
AB 1753 (Low, Chapter 479, Statutes of 2018) allows the DOJ links uniquely serialized prescription pads with CURES.
AB 2086 (Gallagher, Chapter 274, Statutes of 2018) allows prescribers of controlled substances to review a list of patients for whom they are listed as being the prescriber in CURES.
AB 3042 (Takasugi, Chapter 345, Statutes of 2002) first established CURES as a pilot project operating concurrently with the state’s Triplicate Prescription Program.
SB 151 (Burton, Chapter 406, Statutes of 2003) made CURES the state’s permanent prescription tracking program and added Schedule III drugs to the database.
SB 734 (Torlakson, Chapter 487, Statutes of 2005) created the framework to upgrade the CURES prescription database into a searchable, client-facing PDMP.
AB 2986 (Mullin, Chapter 286, Statutes of 2006) added Schedule IV drugs to the CURES database.
SB 809 (DeSaulnier, Chapter 400, Statutes of 2013) established new healing arts license fees to fund the development and maintenance a new and improved “CURES 2.0” database.
SB 482 (Lara, Chapter 708, Statutes of 2016) mandated that health practitioners consult a patient’s history in CURES prior to prescribing them a Schedule II, III, or IV controlled substance for the first time and then at least once every four months as long as the prescription continued to be renewed.
AB 40 (Santiago, Chapter 607, Statutes of 2017) required the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements.
ARGUMENTS IN SUPPORT:
The California Medical Association (CMA) supports the bell. The CMA states that “In order for a physician to make the most informed decision when prescribing a controlled substance to a patient, they must know what medication the patient is currently taking. This bill would ensure that the physician has up-to-date information on any controlled substances a patient is taking to within one day of dispensing. This information is critically important to both the physician and the safety of the patient.”
ARGUMENTS IN OPPOSITION:
None on file.
REGISTERED SUPPORT:
California Chapter of the American College of Emergency Physicians
California Dental Association
California Medical Association
County Behavioral Health Directors Association
REGISTERED OPPOSITION:
None on file.
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301
Bill Author
Bill Co-Author(s):